Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8070504,peak plasma concentration (Cmax),"The formulations differed markedly in their kinetic characteristics: the peak plasma concentration (Cmax) of R,S-metoprolol after administration of the conventional formulation was 140 ng.",Receptor binding assays in analysing the bioavailability and pharmacodynamic bioequivalence of active drug moieties. A study of metoprolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070504/),ng,140,4979,DB00264,Metoprolol
,8070504,AUC0-24 h,"ml-1, (n = 7) and it was approximately one-third of that after the sustained-release formulation, 49 ng.ml-1, (n = 6); the AUC0-24 h-values for the formulations were 700 and 310 ng.h.ml-1, respectively.",Receptor binding assays in analysing the bioavailability and pharmacodynamic bioequivalence of active drug moieties. A study of metoprolol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070504/),[h·ng] / [ml],700,4980,DB00264,Metoprolol
,8070504,AUC0-24 h,"ml-1, (n = 7) and it was approximately one-third of that after the sustained-release formulation, 49 ng.ml-1, (n = 6); the AUC0-24 h-values for the formulations were 700 and 310 ng.h.ml-1, respectively.",Receptor binding assays in analysing the bioavailability and pharmacodynamic bioequivalence of active drug moieties. A study of metoprolol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070504/),[h·ng] / [ml],310,4981,DB00264,Metoprolol
,8070504,Cmax,The Cmax for the beta 1-adrenoceptor binding component of metoprolol was 180 ng.,Receptor binding assays in analysing the bioavailability and pharmacodynamic bioequivalence of active drug moieties. A study of metoprolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070504/),ng,180,4982,DB00264,Metoprolol
,8070504,AUC0-24 h,The corresponding AUC0-24 h-values for the receptor binding component were 920 and 470 ng.h.ml-1 (n = 7).,Receptor binding assays in analysing the bioavailability and pharmacodynamic bioequivalence of active drug moieties. A study of metoprolol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070504/),[h·ng] / [ml],920,4983,DB00264,Metoprolol
,8070504,AUC0-24 h,The corresponding AUC0-24 h-values for the receptor binding component were 920 and 470 ng.h.ml-1 (n = 7).,Receptor binding assays in analysing the bioavailability and pharmacodynamic bioequivalence of active drug moieties. A study of metoprolol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070504/),[h·ng] / [ml],470,4984,DB00264,Metoprolol
,11596322,peak times,"The peak times of plasma (+)-Met and (-)-Met concentration in dogs were 24 +/- 5 and 30 +/- 5 min, respectively.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),min,24,6087,DB00264,Metoprolol
,11596322,peak times,"The peak times of plasma (+)-Met and (-)-Met concentration in dogs were 24 +/- 5 and 30 +/- 5 min, respectively.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),min,30,6088,DB00264,Metoprolol
,11596322,peak times,"But the peak times of drug inhibitory effects on Vmax, dp/dtmax, LVSP, SBP and HR were about 90-120 min, showing the hysteresis loops.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),min,90-120,6089,DB00264,Metoprolol
,11596322,Ce50,"The Ce50 values of inhibitory effects on Vmax, dp/dtmax and HR of (+)-Met were 250 +/- 80, 450 +/- 210, 520 +/- 210 micrograms.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),μg,250,6090,DB00264,Metoprolol
,11596322,Ce50,"The Ce50 values of inhibitory effects on Vmax, dp/dtmax and HR of (+)-Met were 250 +/- 80, 450 +/- 210, 520 +/- 210 micrograms.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),μg,450,6091,DB00264,Metoprolol
,11596322,Ce50,"The Ce50 values of inhibitory effects on Vmax, dp/dtmax and HR of (+)-Met were 250 +/- 80, 450 +/- 210, 520 +/- 210 micrograms.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),μg,520,6092,DB00264,Metoprolol
,11596322,dp/dtmax,"The Ce50 values of inhibitory effects on Vmax, dp/dtmax and HR of (+)-Met were 250 +/- 80, 450 +/- 210, 520 +/- 210 micrograms.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),μg,250,6093,DB00264,Metoprolol
,11596322,dp/dtmax,"The Ce50 values of inhibitory effects on Vmax, dp/dtmax and HR of (+)-Met were 250 +/- 80, 450 +/- 210, 520 +/- 210 micrograms.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),μg,450,6094,DB00264,Metoprolol
,11596322,dp/dtmax,"The Ce50 values of inhibitory effects on Vmax, dp/dtmax and HR of (+)-Met were 250 +/- 80, 450 +/- 210, 520 +/- 210 micrograms.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),μg,520,6095,DB00264,Metoprolol
,11596322,H,"The Ce50 values of inhibitory effects on Vmax, dp/dtmax and HR of (+)-Met were 250 +/- 80, 450 +/- 210, 520 +/- 210 micrograms.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),μg,250,6096,DB00264,Metoprolol
,11596322,H,"The Ce50 values of inhibitory effects on Vmax, dp/dtmax and HR of (+)-Met were 250 +/- 80, 450 +/- 210, 520 +/- 210 micrograms.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),μg,450,6097,DB00264,Metoprolol
,11596322,H,"The Ce50 values of inhibitory effects on Vmax, dp/dtmax and HR of (+)-Met were 250 +/- 80, 450 +/- 210, 520 +/- 210 micrograms.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),μg,520,6098,DB00264,Metoprolol
,11596322,L-1,"L-1 and those of (-)-Met were 70 +/- 30, 70 +/- 40 and 82 +/- 27 micrograms.L-1, respectively.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),[μg] / [l],70,6099,DB00264,Metoprolol
,11596322,L-1,"L-1 and those of (-)-Met were 70 +/- 30, 70 +/- 40 and 82 +/- 27 micrograms.L-1, respectively.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),[μg] / [l],70,6100,DB00264,Metoprolol
,11596322,L-1,"L-1 and those of (-)-Met were 70 +/- 30, 70 +/- 40 and 82 +/- 27 micrograms.L-1, respectively.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),[μg] / [l],82,6101,DB00264,Metoprolol
,11596322,Ce50+,"The values of Ce50+/Ce50- were 3.7, 6.8 and 6.3, indicating that the inhibitory effects on Vmax, dp/dtmax and HR of (-)-Met were stronger than those of (+)-Met in dogs.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),,3.7,6102,DB00264,Metoprolol
,11596322,Ce50+,"The values of Ce50+/Ce50- were 3.7, 6.8 and 6.3, indicating that the inhibitory effects on Vmax, dp/dtmax and HR of (-)-Met were stronger than those of (+)-Met in dogs.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),,6.8,6103,DB00264,Metoprolol
,11596322,Ce50+,"The values of Ce50+/Ce50- were 3.7, 6.8 and 6.3, indicating that the inhibitory effects on Vmax, dp/dtmax and HR of (-)-Met were stronger than those of (+)-Met in dogs.",[Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596322/),,6.3,6104,DB00264,Metoprolol
,2979275,area under the curve,"In the chronic dosing study, the area under the curve for metoprolol was also significantly higher on cimetidine (1796 ng h/ml; P less than 0.001) whereas the area under the curve on ranitidine (1258 ng h/ml) was comparable to that on placebo (1183 ng h/ml).",The effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979275/),[h·ng] / [ml],1796,6425,DB00264,Metoprolol
,2979275,area under the curve,"In the chronic dosing study, the area under the curve for metoprolol was also significantly higher on cimetidine (1796 ng h/ml; P less than 0.001) whereas the area under the curve on ranitidine (1258 ng h/ml) was comparable to that on placebo (1183 ng h/ml).",The effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979275/),[h·ng] / [ml],1258,6426,DB00264,Metoprolol
,2979275,area under the curve,"In the chronic dosing study, the area under the curve for metoprolol was also significantly higher on cimetidine (1796 ng h/ml; P less than 0.001) whereas the area under the curve on ranitidine (1258 ng h/ml) was comparable to that on placebo (1183 ng h/ml).",The effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979275/),[h·ng] / [ml],1183,6427,DB00264,Metoprolol
,6840171,systemic availability,"The mean systemic availability was about 39% in the elderly, which is lower than the mean of 55% observed in a control group of young volunteers who received 50 mg b.i.d.","Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840171/),%,39,10420,DB00264,Metoprolol
,6840171,systemic availability,"The mean systemic availability was about 39% in the elderly, which is lower than the mean of 55% observed in a control group of young volunteers who received 50 mg b.i.d.","Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840171/),%,55,10421,DB00264,Metoprolol
,7379442,elimination half-life,In 14 the elimination half-life of metoprolol after single 100-mg doses (4.1 +/- 0.6 hr) was prolonged (p less than 0.05) after 6 to 12 wk of therapy (5.6 +/- 0.7 hr).,Metoprolol kinetics and dose response in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379442/),h,4.1,18849,DB00264,Metoprolol
,7379442,elimination half-life,In 14 the elimination half-life of metoprolol after single 100-mg doses (4.1 +/- 0.6 hr) was prolonged (p less than 0.05) after 6 to 12 wk of therapy (5.6 +/- 0.7 hr).,Metoprolol kinetics and dose response in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379442/),h,5.6,18850,DB00264,Metoprolol
,18020541,area under the concentration-time curve from time zero to time t,A 3-fold improvement in bioavailability was observed with the TDDS form over oral therapy as shown by the extent of absorption indicated by the mean area under the concentration-time curve from time zero to time t values for tablets (451.98 ng x h/mL) and TDDS (1552.66 ng x h/mL).,Comparative bioavailability of metoprolol tartrate after oral and transdermal administration in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18020541/),[h·ng] / [ml],451.98,19761,DB00264,Metoprolol
,18020541,area under the concentration-time curve from time zero to time t,A 3-fold improvement in bioavailability was observed with the TDDS form over oral therapy as shown by the extent of absorption indicated by the mean area under the concentration-time curve from time zero to time t values for tablets (451.98 ng x h/mL) and TDDS (1552.66 ng x h/mL).,Comparative bioavailability of metoprolol tartrate after oral and transdermal administration in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18020541/),[h·ng] / [ml],1552.66,19762,DB00264,Metoprolol
,18020541,maximum plasma concentration,"Although the maximum plasma concentration was higher for the tablet form than the TDDS (77.67 +/- 23.33 vs 51.16 +/- 16.61 ng/mL), the variable absorption profile, which is a characteristic feature of oral therapy, was quite evident.",Comparative bioavailability of metoprolol tartrate after oral and transdermal administration in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18020541/),[ng] / [ml],77.67,19763,DB00264,Metoprolol
,18020541,maximum plasma concentration,"Although the maximum plasma concentration was higher for the tablet form than the TDDS (77.67 +/- 23.33 vs 51.16 +/- 16.61 ng/mL), the variable absorption profile, which is a characteristic feature of oral therapy, was quite evident.",Comparative bioavailability of metoprolol tartrate after oral and transdermal administration in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18020541/),[ng] / [ml],51.16,19764,DB00264,Metoprolol
,7624261,oral clearance,"Mean oral clearance values for S- and R-metoprolol were 1320 and 2346 ml/minute, respectively.","Lymphocyte beta 2-receptor activity, metoprolol kinetics, and response to metoprolol in hypertensive black men. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624261/),[ml] / [min],1320,20838,DB00264,Metoprolol
,7624261,oral clearance,"Mean oral clearance values for S- and R-metoprolol were 1320 and 2346 ml/minute, respectively.","Lymphocyte beta 2-receptor activity, metoprolol kinetics, and response to metoprolol in hypertensive black men. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624261/),[ml] / [min],2346,20839,DB00264,Metoprolol
,27795624,Drug requirement,Drug requirement increased from 4.5 ± 3.6 to 8.5 ± 6.4 units (P < 0.0001).,Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795624/),,4.5,21462,DB00264,Metoprolol
,27795624,Drug requirement,Drug requirement increased from 4.5 ± 3.6 to 8.5 ± 6.4 units (P < 0.0001).,Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795624/),,8.5,21463,DB00264,Metoprolol
,27795624,time to first increase in dose,Mean time to first increase in dose was 6.5 ± 3.6 days.,Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795624/),d,6.5,21464,DB00264,Metoprolol
,30317077,run time,"The separation was carried out on a ZORBAX Eclipse Plus C18 Rapid Resolution High Definition column with a gradient elution, using water containing 0.1% formic acid (A) and acetonitrile (B) in a run time of only 3.0 min.","A UHPLC-MS/MS method coupled with liquid-liquid extraction for the quantitation of phenacetin, omeprazole, metoprolol, midazolam and their metabolites in rat plasma and its application to the study of four CYP450 activities. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30317077/),min,3.0,22823,DB00264,Metoprolol
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],283.7,23877,DB00264,Metoprolol
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],295.7,23878,DB00264,Metoprolol
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],416.8,23879,DB00264,Metoprolol
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],540.7,23880,DB00264,Metoprolol
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],292.0,23881,DB00264,Metoprolol
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],416.8,23882,DB00264,Metoprolol
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],424.9,23883,DB00264,Metoprolol
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],540.7,23884,DB00264,Metoprolol
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],595.3,23885,DB00264,Metoprolol
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],760.6,23886,DB00264,Metoprolol
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],788.7,23887,DB00264,Metoprolol
,2609974,K'r,It was found that the in vitro release characteristics showed basically first-order kinetics (K'r = 0.1651 h-1); a tentative two-year expiration date on M-HBS was established; the gamma-scintiphotographic study after oral ingestion showed that M-HBS was retained in human stomach for longer time (5-6 h) than the conventional metoprolol tablet (1-1.5 h).,[Development and pharmacokinetic study of metoprolol tartrate controlled-release tablet remaining-floating in stomach]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609974/),1/[h],0.1651,24159,DB00264,Metoprolol
,2609974,Ka,"The parameters were calculated using a NONLIN computer program with the values of Ka, K, Vd, tmax, cmax, being 0.1944 h-1, 0.1867 h-1, 2.813, 5.247 h, 125.1 ng/ml, respectively.",[Development and pharmacokinetic study of metoprolol tartrate controlled-release tablet remaining-floating in stomach]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609974/),1/[h],0.1944,24160,DB00264,Metoprolol
,2609974,cmax,"The parameters were calculated using a NONLIN computer program with the values of Ka, K, Vd, tmax, cmax, being 0.1944 h-1, 0.1867 h-1, 2.813, 5.247 h, 125.1 ng/ml, respectively.",[Development and pharmacokinetic study of metoprolol tartrate controlled-release tablet remaining-floating in stomach]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609974/),h,5.247,24161,DB00264,Metoprolol
,2609974,cmax,"The parameters were calculated using a NONLIN computer program with the values of Ka, K, Vd, tmax, cmax, being 0.1944 h-1, 0.1867 h-1, 2.813, 5.247 h, 125.1 ng/ml, respectively.",[Development and pharmacokinetic study of metoprolol tartrate controlled-release tablet remaining-floating in stomach]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609974/),[ng] / [ml],125.1,24162,DB00264,Metoprolol
,7737240,bioavailability,"The bioavailability of 7/95, 14/190 and 21/285",Stable isotope methodology for studying the performance of metoprolol Oros tablets in comparison to conventional and slow release formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7737240/),,7,24564,DB00264,Metoprolol
,7737240,bioavailability,"The bioavailability of 7/95, 14/190 and 21/285",Stable isotope methodology for studying the performance of metoprolol Oros tablets in comparison to conventional and slow release formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7737240/),,14,24565,DB00264,Metoprolol
,7737240,bioavailability,"The bioavailability of 7/95, 14/190 and 21/285",Stable isotope methodology for studying the performance of metoprolol Oros tablets in comparison to conventional and slow release formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7737240/),,21,24566,DB00264,Metoprolol
,23303553,total chromatographic run time,"The total chromatographic run time was 4.0 min and the elution of FDP, MPL and IS occurred at 1.05, 2.59 and 1.65 min, respectively.",Validated LC-ESI-MS/MS method for simultaneous quantitation of felodipine and metoprolol in rat plasma: application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23303553/),min,4.0,25739,DB00264,Metoprolol
more,26592698,gastric residence,In vitro wash off and buoyancy test in gastric media revealed that the beads containing CaCO3 has gastric residence of more than 12 h.,Tapioca starch blended alginate mucoadhesive-floating beads for intragastric delivery of Metoprolol Tartrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26592698/),,12,27155,DB00264,Metoprolol
,26592698,relative oral bioavailability,"Pharmacokinetic study performed in rabbit model showed that the relative oral bioavailability of MT after administration of oral solution, sustain release and optimized formulation was 51%, 67% and 87%, respectively.",Tapioca starch blended alginate mucoadhesive-floating beads for intragastric delivery of Metoprolol Tartrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26592698/),%,51,27156,DB00264,Metoprolol
,26592698,relative oral bioavailability,"Pharmacokinetic study performed in rabbit model showed that the relative oral bioavailability of MT after administration of oral solution, sustain release and optimized formulation was 51%, 67% and 87%, respectively.",Tapioca starch blended alginate mucoadhesive-floating beads for intragastric delivery of Metoprolol Tartrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26592698/),%,67,27157,DB00264,Metoprolol
,26592698,relative oral bioavailability,"Pharmacokinetic study performed in rabbit model showed that the relative oral bioavailability of MT after administration of oral solution, sustain release and optimized formulation was 51%, 67% and 87%, respectively.",Tapioca starch blended alginate mucoadhesive-floating beads for intragastric delivery of Metoprolol Tartrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26592698/),%,87,27158,DB00264,Metoprolol
,26114209,Bioavailabilities,"3. Bioavailabilities were ∼100% for caffeine and warfarin, but <25% for omeprazole and metoprolol.","Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114209/),%,∼100,27489,DB00264,Metoprolol
<,26114209,Bioavailabilities,"3. Bioavailabilities were ∼100% for caffeine and warfarin, but <25% for omeprazole and metoprolol.","Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114209/),%,25,27490,DB00264,Metoprolol
,26114209,Bioavailability,"Bioavailability of midazolam was 4% in marmosets, presumably because of contribution of marmoset P450 3A4 expressed in small intestine and liver, with a high catalytic efficiency for midazolam 1'-hydroxylation as evident in the recombinant system.","Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114209/),%,4,27491,DB00264,Metoprolol
,15788540,kinact,"We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.",In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),1/[min],0.17,28928,DB00264,Metoprolol
,15788540,unbound KI,"We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.",In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),μM,0.315,28929,DB00264,Metoprolol
,15788540,degradation half-life,"We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.",In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),h,51,28930,DB00264,Metoprolol
,15788540,degradation half-life,Simulation of the sensitivities of these predictions to model inputs suggests a 2-fold underprediction of interaction magnitude when a CYP2D6 degradation half-life of 14 h (reported for rat CYP3A) is used.,In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),h,14,28931,DB00264,Metoprolol
,11393712,R/S ratio,"Following a single metoprolol oral administration of 100 mg racemic metoprolol tartrate, stereoselective pharmacokinetic analysis showed that urinary acidic metabolite 3 of metoprolol accounted for 62.3% of the dose with an R/S ratio of 1.23 and urinary unchanged metoprolol 1 accounted for 6.3% of the dose with an R/S ratio of 0.72.",Enantioselective determination of metoprolol and major metabolites in human urine by capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11393712/),,1.23,29466,DB00264,Metoprolol
,11393712,R/S ratio,"Following a single metoprolol oral administration of 100 mg racemic metoprolol tartrate, stereoselective pharmacokinetic analysis showed that urinary acidic metabolite 3 of metoprolol accounted for 62.3% of the dose with an R/S ratio of 1.23 and urinary unchanged metoprolol 1 accounted for 6.3% of the dose with an R/S ratio of 0.72.",Enantioselective determination of metoprolol and major metabolites in human urine by capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11393712/),,0.72,29467,DB00264,Metoprolol
,6746155,infusion time,The lidocaine dose was 100 mg and the infusion time 12 minutes.,Pharmacokinetics of lidocaine in healthy individuals pretreated with multiple doses of metoprolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6746155/),min,12,31189,DB00264,Metoprolol
,8846626,GI transit time,"For example, the median GI transit time for both oxprenolol and metoprolol Oros drug delivery systems has been reported as 27.4 hours, with individual times ranging from 5.1 to 58.3 hours.","The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846626/),h,27.4,33421,DB00264,Metoprolol
,6102500,fraction of the oral dose systemically available,The fraction of the oral dose systemically available during steady-state was 59 +/- 9% in the renal patients and 55 +/- 7% in the control group.,Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6102500/),%,59,35626,DB00264,Metoprolol
,6102500,fraction of the oral dose systemically available,The fraction of the oral dose systemically available during steady-state was 59 +/- 9% in the renal patients and 55 +/- 7% in the control group.,Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6102500/),%,55,35627,DB00264,Metoprolol
,6102500,Total body clearance,Total body clearance in the patients with renal failure was 1.0 +/- 0.1 L/min and in the healthy subjects it was 0.8 +/- 0.1 L/min.,Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6102500/),[l] / [min],1.0,35628,DB00264,Metoprolol
,6102500,Total body clearance,Total body clearance in the patients with renal failure was 1.0 +/- 0.1 L/min and in the healthy subjects it was 0.8 +/- 0.1 L/min.,Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6102500/),[l] / [min],0.8,35629,DB00264,Metoprolol
,6102500,elimination half-life,"The corresponding values for the elimination half-life were 4.6 +/- 1.2h and 4.1 +/- 1.0h, respectively.",Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6102500/),h,4.6,35630,DB00264,Metoprolol
,6102500,elimination half-life,"The corresponding values for the elimination half-life were 4.6 +/- 1.2h and 4.1 +/- 1.0h, respectively.",Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6102500/),h,4.1,35631,DB00264,Metoprolol
,2565392,apparent IC50,"The apparent IC50 values varied between 42 and 68 ng/ml (mean, 54 ng/ml) for metoprolol and between 3.6 and 4.7 ng/ml (mean, 4.1 ng/ml) for oxprenolol.",A nonsteady-state agonist antagonist interaction model using plasma potassium concentrations to quantify the beta-2 selectivity of beta blockers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565392/),[ng] / [ml],42 and 68,35946,DB00264,Metoprolol
,2565392,apparent IC50,"The apparent IC50 values varied between 42 and 68 ng/ml (mean, 54 ng/ml) for metoprolol and between 3.6 and 4.7 ng/ml (mean, 4.1 ng/ml) for oxprenolol.",A nonsteady-state agonist antagonist interaction model using plasma potassium concentrations to quantify the beta-2 selectivity of beta blockers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565392/),[ng] / [ml],54,35947,DB00264,Metoprolol
,2565392,apparent IC50,"The apparent IC50 values varied between 42 and 68 ng/ml (mean, 54 ng/ml) for metoprolol and between 3.6 and 4.7 ng/ml (mean, 4.1 ng/ml) for oxprenolol.",A nonsteady-state agonist antagonist interaction model using plasma potassium concentrations to quantify the beta-2 selectivity of beta blockers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565392/),[ng] / [ml],4.1,35948,DB00264,Metoprolol
,3061720,systemic bioavailability,"It is well absorbed after oral administration, but systemic bioavailability is only 12% after a 300-mg dose.",Propafenone: a new antiarrhythmic agent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),%,12,37633,DB00264,Metoprolol
,3061720,elimination half-life,"Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers.",Propafenone: a new antiarrhythmic agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),h,5.5,37634,DB00264,Metoprolol
,3061720,elimination half-life,"Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers.",Propafenone: a new antiarrhythmic agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),h,17.2,37635,DB00264,Metoprolol
,16733693,E(max),"Although a greater maximal effect (E(max)) for the antihypertensive effect of MET was observed in SH rats (WKY: E(max): -17+/-1 mmHg; SH: E(max): -28+/-4 mmHg; P<0.05 versus WKY rats), no differences were found in the concentration yielding half-maximal response (IC(50)) comparing SH (IC(50): 583+/-146 ng x ml(-1)) and WKY animals (IC(50): 639+/-187 ng x ml(-1)).",Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16733693/),mmhg,-17,39506,DB00264,Metoprolol
,16733693,E(max),"Although a greater maximal effect (E(max)) for the antihypertensive effect of MET was observed in SH rats (WKY: E(max): -17+/-1 mmHg; SH: E(max): -28+/-4 mmHg; P<0.05 versus WKY rats), no differences were found in the concentration yielding half-maximal response (IC(50)) comparing SH (IC(50): 583+/-146 ng x ml(-1)) and WKY animals (IC(50): 639+/-187 ng x ml(-1)).",Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16733693/),mmh,-28,39507,DB00264,Metoprolol
,16733693,IC(50),"Although a greater maximal effect (E(max)) for the antihypertensive effect of MET was observed in SH rats (WKY: E(max): -17+/-1 mmHg; SH: E(max): -28+/-4 mmHg; P<0.05 versus WKY rats), no differences were found in the concentration yielding half-maximal response (IC(50)) comparing SH (IC(50): 583+/-146 ng x ml(-1)) and WKY animals (IC(50): 639+/-187 ng x ml(-1)).",Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16733693/),[ng] / [ml],583,39508,DB00264,Metoprolol
,16733693,IC(50),"Although a greater maximal effect (E(max)) for the antihypertensive effect of MET was observed in SH rats (WKY: E(max): -17+/-1 mmHg; SH: E(max): -28+/-4 mmHg; P<0.05 versus WKY rats), no differences were found in the concentration yielding half-maximal response (IC(50)) comparing SH (IC(50): 583+/-146 ng x ml(-1)) and WKY animals (IC(50): 639+/-187 ng x ml(-1)).",Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16733693/),[ng] / [ml],639,39509,DB00264,Metoprolol
,16733693,IC(50),"The bradycardic effect of MET was greater in SH rats (E(max): -29+/-1%, P<0.05 versus WKY rats) than in WK animals (E(max): -22+/-2%), but no differences were observed in the IC(50) comparing both experimental groups (WKY: IC(50): 187+/-53 ng x ml(-1); SH: IC(50): 216+/-62 ng x ml(-1)).",Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16733693/),[ng] / [ml],187,39510,DB00264,Metoprolol
,16733693,IC(50),"The bradycardic effect of MET was greater in SH rats (E(max): -29+/-1%, P<0.05 versus WKY rats) than in WK animals (E(max): -22+/-2%), but no differences were observed in the IC(50) comparing both experimental groups (WKY: IC(50): 187+/-53 ng x ml(-1); SH: IC(50): 216+/-62 ng x ml(-1)).",Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16733693/),[ng] / [ml],216,39511,DB00264,Metoprolol
,16733693,Vd,"Pharmacokinetic analysis shows that the volume of distribution of MET was greater in SH rats (Vd: 3.4+/-0.5 l, P<0.05 versus WKY rats) with regard to Wistar Kyoto (WKY) animals (Vd: 1.9+/-0.2 l).",Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16733693/),l,3.4,39512,DB00264,Metoprolol
,16733693,Vd,"Pharmacokinetic analysis shows that the volume of distribution of MET was greater in SH rats (Vd: 3.4+/-0.5 l, P<0.05 versus WKY rats) with regard to Wistar Kyoto (WKY) animals (Vd: 1.9+/-0.2 l).",Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16733693/),l,1.9,39513,DB00264,Metoprolol
,16005691,chromatographic run time,The method had a chromatographic run time of 3.5 min and a linear calibration curve over the range 0.1-200 ng ml(-1) (r2>0.997992).,Quantification of carvedilol in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005691/),min,3.5,46192,DB00264,Metoprolol
,9349926,Initial pain intensity,"Initial pain intensity was 5.9 (arbitrary units) and 5.4 in the groups with and without signs of transmural myocardial damage, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),,5.9,48512,DB00264,Metoprolol
,9349926,Initial pain intensity,"Initial pain intensity was 5.9 (arbitrary units) and 5.4 in the groups with and without signs of transmural myocardial damage, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),,5.4,48513,DB00264,Metoprolol
,9349926,terminal half-life,The terminal half-life of unchanged metoprolol ranged from 2.5 to 8.5 h in group 1 and from 2.2 to 5.2 h in group 2.,Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),h,2.5 to 8.5,48514,DB00264,Metoprolol
,9349926,terminal half-life,The terminal half-life of unchanged metoprolol ranged from 2.5 to 8.5 h in group 1 and from 2.2 to 5.2 h in group 2.,Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),h,2.2 to 5.2,48515,DB00264,Metoprolol
,9349926,half-life,"In group 1, metoprolol half-life was 4.5 h and total plasma clearance (CL) 54.1 1.h-1.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),h,4.5,48516,DB00264,Metoprolol
,9349926,total plasma clearance (CL),"In group 1, metoprolol half-life was 4.5 h and total plasma clearance (CL) 54.1 1.h-1.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),[1] / [h],54.1,48517,DB00264,Metoprolol
,9349926,half-life,"In group 2, the metoprolol half-life was 3.7 h and total plasma clearance 75.4 1.h-1.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),h,3.7,48518,DB00264,Metoprolol
,9349926,total plasma clearance,"In group 2, the metoprolol half-life was 3.7 h and total plasma clearance 75.4 1.h-1.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),[1] / [h],75.4,48519,DB00264,Metoprolol
,9349926,maximal concentrations in plasma (Cmax),"In groups 1 and 2, maximal concentrations in plasma (Cmax) were 143 and 135 nmol.1(-1) for alpha-hydroxymetoprolol and 2830 and 1653 nmol.1(-1) for metoprolol, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),nM,143,48520,DB00264,Metoprolol
,9349926,maximal concentrations in plasma (Cmax),"In groups 1 and 2, maximal concentrations in plasma (Cmax) were 143 and 135 nmol.1(-1) for alpha-hydroxymetoprolol and 2830 and 1653 nmol.1(-1) for metoprolol, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),nM,135,48521,DB00264,Metoprolol
,9349926,maximal concentrations in plasma (Cmax),"In groups 1 and 2, maximal concentrations in plasma (Cmax) were 143 and 135 nmol.1(-1) for alpha-hydroxymetoprolol and 2830 and 1653 nmol.1(-1) for metoprolol, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),nM,2830,48522,DB00264,Metoprolol
,9349926,maximal concentrations in plasma (Cmax),"In groups 1 and 2, maximal concentrations in plasma (Cmax) were 143 and 135 nmol.1(-1) for alpha-hydroxymetoprolol and 2830 and 1653 nmol.1(-1) for metoprolol, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),nM,1653,48523,DB00264,Metoprolol
,27468378,volume of,"Metoprolol was modeled using a one-compartment model and resulted in the following population pharmacokinetic parameters: volume of distribution, V=38L (CV=155%), clearance rates, CL-Men=105L/hour and CL-Women=59.1L/hour (38%), time lag, Tlag=0.469 hour (CV=17%), and the absorption rate constant, Ka=0.235 hr-1 (CV=23%).",Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468378/),l,38,49217,DB00264,Metoprolol
,27468378,CL-Men,"Metoprolol was modeled using a one-compartment model and resulted in the following population pharmacokinetic parameters: volume of distribution, V=38L (CV=155%), clearance rates, CL-Men=105L/hour and CL-Women=59.1L/hour (38%), time lag, Tlag=0.469 hour (CV=17%), and the absorption rate constant, Ka=0.235 hr-1 (CV=23%).",Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468378/),[l] / [h],105,49218,DB00264,Metoprolol
,27468378,CL-Women,"Metoprolol was modeled using a one-compartment model and resulted in the following population pharmacokinetic parameters: volume of distribution, V=38L (CV=155%), clearance rates, CL-Men=105L/hour and CL-Women=59.1L/hour (38%), time lag, Tlag=0.469 hour (CV=17%), and the absorption rate constant, Ka=0.235 hr-1 (CV=23%).",Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468378/),[l] / [h],59.1,49219,DB00264,Metoprolol
,27468378,"time lag, Tlag","Metoprolol was modeled using a one-compartment model and resulted in the following population pharmacokinetic parameters: volume of distribution, V=38L (CV=155%), clearance rates, CL-Men=105L/hour and CL-Women=59.1L/hour (38%), time lag, Tlag=0.469 hour (CV=17%), and the absorption rate constant, Ka=0.235 hr-1 (CV=23%).",Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468378/),h,0.469,49220,DB00264,Metoprolol
,27468378,"absorption rate constant, Ka","Metoprolol was modeled using a one-compartment model and resulted in the following population pharmacokinetic parameters: volume of distribution, V=38L (CV=155%), clearance rates, CL-Men=105L/hour and CL-Women=59.1L/hour (38%), time lag, Tlag=0.469 hour (CV=17%), and the absorption rate constant, Ka=0.235 hr-1 (CV=23%).",Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468378/),1/[h],0.235,49221,DB00264,Metoprolol
,2312778,relative bioavailability,The relative bioavailability of CR/ZOK to CT was 69.0%.,Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312778/),%,69.0,49766,DB00264,Metoprolol
,1432569,steady-state plasma concentrations,The distribution of metoprolol tartrate (MPL) into the brain and cerebrospinal fluid (CSF) from plasma was determined at 2 different steady-state plasma concentrations (2 and 20 nmol/ml) and following intravenous bolus administration (100 nmol/kg) in rats.,Brain and cerebrospinal fluid distributions of metoprolol in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432569/),[nM] / [ml],2,52946,DB00264,Metoprolol
,1432569,steady-state plasma concentrations,The distribution of metoprolol tartrate (MPL) into the brain and cerebrospinal fluid (CSF) from plasma was determined at 2 different steady-state plasma concentrations (2 and 20 nmol/ml) and following intravenous bolus administration (100 nmol/kg) in rats.,Brain and cerebrospinal fluid distributions of metoprolol in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432569/),[nM] / [ml],20,52947,DB00264,Metoprolol
,1432569,brain-,"Under steady-state condition, no difference in the brain and CSF distributions of MPL was observed between 2 different plasma MPL concentrations, and the value of brain- or CSF-to-plasma partition coefficients were 5.7 and 1.5, respectively.",Brain and cerebrospinal fluid distributions of metoprolol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432569/),,5.7,52948,DB00264,Metoprolol
,1432569,CSF-to-plasma partition coefficients,"Under steady-state condition, no difference in the brain and CSF distributions of MPL was observed between 2 different plasma MPL concentrations, and the value of brain- or CSF-to-plasma partition coefficients were 5.7 and 1.5, respectively.",Brain and cerebrospinal fluid distributions of metoprolol in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432569/),,1.5,52949,DB00264,Metoprolol
,7988629,tmax,The pharmacokinetic variables of the two formulations were very similar except for the longer tmax of 4.4 h for diltiazem CR in comparison to 2.9 h for the plain tablets.,Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),h,4.4,52976,DB00264,Metoprolol
,7988629,tmax,The pharmacokinetic variables of the two formulations were very similar except for the longer tmax of 4.4 h for diltiazem CR in comparison to 2.9 h for the plain tablets.,Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),h,2.9,52977,DB00264,Metoprolol
,7988629,relative bioavailability,The mean relative bioavailability of diltiazem CR in comparison with plain tablets was 1.14.,Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),,1.14,52978,DB00264,Metoprolol
,7988629,maximum workload,"The clinical study showed that after four weeks on diltiazem CR 120 mg b.i.d. or diltiazem plain tablets 60 mg q.i.d. in addition to metoprolol, there were significant decreases in weekly anginal attacks from 11 to 5 attacks/week, the number of nitroglycerin tablets consumed from 6 to 3 tablets/week, and an increase in the maximum workload from 116 to 126 and 123 W for diltiazem CR and plain diltiazem tablets, respectively, as compared to placebo.",Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),w,116,52979,DB00264,Metoprolol
,7988629,maximum workload,"The clinical study showed that after four weeks on diltiazem CR 120 mg b.i.d. or diltiazem plain tablets 60 mg q.i.d. in addition to metoprolol, there were significant decreases in weekly anginal attacks from 11 to 5 attacks/week, the number of nitroglycerin tablets consumed from 6 to 3 tablets/week, and an increase in the maximum workload from 116 to 126 and 123 W for diltiazem CR and plain diltiazem tablets, respectively, as compared to placebo.",Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),w,126,52980,DB00264,Metoprolol
,7988629,maximum workload,"The clinical study showed that after four weeks on diltiazem CR 120 mg b.i.d. or diltiazem plain tablets 60 mg q.i.d. in addition to metoprolol, there were significant decreases in weekly anginal attacks from 11 to 5 attacks/week, the number of nitroglycerin tablets consumed from 6 to 3 tablets/week, and an increase in the maximum workload from 116 to 126 and 123 W for diltiazem CR and plain diltiazem tablets, respectively, as compared to placebo.",Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),w,123,52981,DB00264,Metoprolol
,24666338,activated partial th,"Eleven hours post overdose extracorporeal elimination was implemented as the patient developed worsening coagulopathy with an elevated international normalized ratio of 11 IU, an activated partial thromboplastin time of 115 s, and had renal impairment with a creatinine of 158 μmol/L.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),s,115,53236,DB00264,Metoprolol
,24666338,peak serum dabigatran level,"This patient developed a peak serum dabigatran level of 1560 ng/ml, 11 h postoverdose.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),[ng] / [ml],1560,53237,DB00264,Metoprolol
,24666338,clearance,"Clearance of dabigatran via continuous veno-venous hemodiafiltration was calculated, using both the recovery and A-V pair methods, with a mean clearance of 58.1 and 31.9 ml/h, respectively, and a calculated mean extraction ratio of 0.2.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),[ml] / [h],58.1,53238,DB00264,Metoprolol
,24666338,clearance,"Clearance of dabigatran via continuous veno-venous hemodiafiltration was calculated, using both the recovery and A-V pair methods, with a mean clearance of 58.1 and 31.9 ml/h, respectively, and a calculated mean extraction ratio of 0.2.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),[ml] / [h],31.9,53239,DB00264,Metoprolol
,24666338,extraction ratio,"Clearance of dabigatran via continuous veno-venous hemodiafiltration was calculated, using both the recovery and A-V pair methods, with a mean clearance of 58.1 and 31.9 ml/h, respectively, and a calculated mean extraction ratio of 0.2.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),,0.2,53240,DB00264,Metoprolol
,18545991,AUCs,"(+/-SD) AUCs of S-metoprolol were 190 +/- 99 ng/ml x h in UMs, 366 +/- 158 in EMs, and 1,804 +/- 300 in PMs.",Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18545991/),[ng] / [h·ml],190,54495,DB00264,Metoprolol
,18545991,AUCs,"(+/-SD) AUCs of S-metoprolol were 190 +/- 99 ng/ml x h in UMs, 366 +/- 158 in EMs, and 1,804 +/- 300 in PMs.",Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18545991/),,366,54496,DB00264,Metoprolol
,18545991,AUCs,"(+/-SD) AUCs of S-metoprolol were 190 +/- 99 ng/ml x h in UMs, 366 +/- 158 in EMs, and 1,804 +/- 300 in PMs.",Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18545991/),,"1,804",54497,DB00264,Metoprolol
,18545991,AUCs,"For R-metoprolol, the AUCs were 127 +/- 72 ng/ml x h in UMs, 261 +/- 126 in EMs, and 1,746 +/- 319 in PMs.",Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18545991/),[ng] / [h·ml],127,54498,DB00264,Metoprolol
,18545991,AUCs,"For R-metoprolol, the AUCs were 127 +/- 72 ng/ml x h in UMs, 261 +/- 126 in EMs, and 1,746 +/- 319 in PMs.",Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18545991/),,261,54499,DB00264,Metoprolol
,18545991,AUCs,"For R-metoprolol, the AUCs were 127 +/- 72 ng/ml x h in UMs, 261 +/- 126 in EMs, and 1,746 +/- 319 in PMs.",Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18545991/),,"1,746",54500,DB00264,Metoprolol
,18545991,half-maximum,"The concentrations of R-metoprolol and S-metoprolol, respectively, needed to obtain a half-maximum reduction in heart rate were estimated as 20 and 21 ng/ml in PMs, 11 and 17 ng/ml in EMs, and 7 and 11 ng/ml in UMs.",Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18545991/),[ng] / [ml],20,54501,DB00264,Metoprolol
,18545991,half-maximum,"The concentrations of R-metoprolol and S-metoprolol, respectively, needed to obtain a half-maximum reduction in heart rate were estimated as 20 and 21 ng/ml in PMs, 11 and 17 ng/ml in EMs, and 7 and 11 ng/ml in UMs.",Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18545991/),[ng] / [ml],21,54502,DB00264,Metoprolol
,18545991,half-maximum,"The concentrations of R-metoprolol and S-metoprolol, respectively, needed to obtain a half-maximum reduction in heart rate were estimated as 20 and 21 ng/ml in PMs, 11 and 17 ng/ml in EMs, and 7 and 11 ng/ml in UMs.",Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18545991/),[ng] / [ml],11,54503,DB00264,Metoprolol
,18545991,half-maximum,"The concentrations of R-metoprolol and S-metoprolol, respectively, needed to obtain a half-maximum reduction in heart rate were estimated as 20 and 21 ng/ml in PMs, 11 and 17 ng/ml in EMs, and 7 and 11 ng/ml in UMs.",Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18545991/),[ng] / [ml],17,54504,DB00264,Metoprolol
,18545991,half-maximum,"The concentrations of R-metoprolol and S-metoprolol, respectively, needed to obtain a half-maximum reduction in heart rate were estimated as 20 and 21 ng/ml in PMs, 11 and 17 ng/ml in EMs, and 7 and 11 ng/ml in UMs.",Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18545991/),[ng] / [ml],7,54505,DB00264,Metoprolol
,16402084,resting heart rates,"In contrast, when compared by codon 49 genotype, Ser49 homozygotes had significantly higher resting heart rates at baseline (untreated) than Gly49 carriers (82+/-10 versus 74+/-11 bpm, respectively, P=0.016).",Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402084/),bpm,82,54534,DB00264,Metoprolol
,16402084,resting heart rates,"In contrast, when compared by codon 49 genotype, Ser49 homozygotes had significantly higher resting heart rates at baseline (untreated) than Gly49 carriers (82+/-10 versus 74+/-11 bpm, respectively, P=0.016).",Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402084/),bpm,74,54535,DB00264,Metoprolol
,7236872,time of peaking (tmax),Propantheline prolonged the absorption phase of atenolol and the time of peaking (tmax) was shifted from 2.1 to 4.5 h.,"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7236872/),h,2.1,56406,DB00264,Metoprolol
,7236872,time of peaking (tmax),Propantheline prolonged the absorption phase of atenolol and the time of peaking (tmax) was shifted from 2.1 to 4.5 h.,"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7236872/),h,4.5,56407,DB00264,Metoprolol
,2382633,bioavailability,All four doses of metoprolol OROS at steady state produced relative pharmacodynamic bioavailability that ranged from 87% to 104% of that produced by equivalent doses of metoprolol CT.,Pharmacokinetic and pharmacodynamic comparison of an osmotic release oral metoprolol tablet and the metoprolol conventional tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2382633/),%,87,56629,DB00264,Metoprolol
,2382633,bioavailability,All four doses of metoprolol OROS at steady state produced relative pharmacodynamic bioavailability that ranged from 87% to 104% of that produced by equivalent doses of metoprolol CT.,Pharmacokinetic and pharmacodynamic comparison of an osmotic release oral metoprolol tablet and the metoprolol conventional tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2382633/),%,104,56630,DB00264,Metoprolol
,10741632,area under the plasma concentration-time curve extrapolated to infinity (AUC),"Paroxetine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC) of (R)- and (S)-metoprolol significantly (169 to 1,340 ng x h/mL [P < .001] and 279 to 1,418 ng x h/mL [P < .001], respectively), with an approximately twofold increase in both maximum plasma concentration and terminal elimination half-life.",Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741632/),[h·ng] / [ml],169,60213,DB00264,Metoprolol
,10741632,area under the plasma concentration-time curve extrapolated to infinity (AUC),"Paroxetine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC) of (R)- and (S)-metoprolol significantly (169 to 1,340 ng x h/mL [P < .001] and 279 to 1,418 ng x h/mL [P < .001], respectively), with an approximately twofold increase in both maximum plasma concentration and terminal elimination half-life.",Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741632/),[h·ng] / [ml],1,60214,DB00264,Metoprolol
,10741632,area under the plasma concentration-time curve extrapolated to infinity (AUC),"Paroxetine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC) of (R)- and (S)-metoprolol significantly (169 to 1,340 ng x h/mL [P < .001] and 279 to 1,418 ng x h/mL [P < .001], respectively), with an approximately twofold increase in both maximum plasma concentration and terminal elimination half-life.",Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741632/),[h·ng] / [ml],279 to,60215,DB00264,Metoprolol
,10741632,AUC ratio,"Furthermore, the (S)/(R) AUC ratio was significantly decreased, from 1.72 to 1.07 (P < .001).",Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741632/),,1.72,60216,DB00264,Metoprolol
,10741632,AUC ratio,"Furthermore, the (S)/(R) AUC ratio was significantly decreased, from 1.72 to 1.07 (P < .001).",Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741632/),,1.07,60217,DB00264,Metoprolol
,10741632,MR,"The mean metoprolol MR was significantly increased, from 0.17 to 5.69 (P < .05).",Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741632/),,0.17,60218,DB00264,Metoprolol
,10741632,MR,"The mean metoprolol MR was significantly increased, from 0.17 to 5.69 (P < .05).",Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741632/),,5.69,60219,DB00264,Metoprolol
,3508566,clearance,"The oral administration of hydralazine hydrochloride, 7.5 mg/kg, 15 min prior to antipyrine administration reduced antipyrine clearance from 9.66 +/- 1.18 to 8.19 +/- 0.76 ml/min/kg (P less than 0.05).",Effect of hydralazine on the elimination of antipyrine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508566/),[ml] / [kg·min],9.66,61364,DB00264,Metoprolol
,3508566,clearance,"The oral administration of hydralazine hydrochloride, 7.5 mg/kg, 15 min prior to antipyrine administration reduced antipyrine clearance from 9.66 +/- 1.18 to 8.19 +/- 0.76 ml/min/kg (P less than 0.05).",Effect of hydralazine on the elimination of antipyrine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508566/),[ml] / [kg·min],8.19,61365,DB00264,Metoprolol
,12482486,Clearances,"Clearances were 0.41 and 0.25 l/h/kg, respectively, for the (+)-(R)- and (-)-(S)-enantiomers.",Enantioselective determination of metoprolol acidic metabolite in plasma and urine using liquid chromatography chiral columns: applications to pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12482486/),[l] / [h·kg],0.41,62447,DB00264,Metoprolol
,12482486,Clearances,"Clearances were 0.41 and 0.25 l/h/kg, respectively, for the (+)-(R)- and (-)-(S)-enantiomers.",Enantioselective determination of metoprolol acidic metabolite in plasma and urine using liquid chromatography chiral columns: applications to pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12482486/),[l] / [h·kg],0.25,62448,DB00264,Metoprolol
,7363534,half-life,"During haemodialysis, however, its concentration decreases with a half-life of 5h.",The pharmacokinetics of metoprolol and its metabolites in dialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363534/),h,5,65125,DB00264,Metoprolol
,15300360,pKb,The pKb of metoprolol was similar in both groups of animals (SO: 7.49+/-0.20; ACo: 7.19+/-0.23).,Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15300360/),,7.49,65932,DB00264,Metoprolol
,15300360,pKb,The pKb of metoprolol was similar in both groups of animals (SO: 7.49+/-0.20; ACo: 7.19+/-0.23).,Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15300360/),,7.19,65933,DB00264,Metoprolol
,15300360,half-maximal effect (pEC50),"There were no differences in maximum response (Emax; SO: -28+/-2.0%, n=5; ACo: -27+/-4%, n=5) or the concentration eliciting a half-maximal effect (pEC50) (SO: 4.9+/-0.2, n=5; ACo: 5.2+/-0.2, n=5) between the experimental groups.",Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15300360/),,4.9,65934,DB00264,Metoprolol
,15300360,half-maximal effect (pEC50),"There were no differences in maximum response (Emax; SO: -28+/-2.0%, n=5; ACo: -27+/-4%, n=5) or the concentration eliciting a half-maximal effect (pEC50) (SO: 4.9+/-0.2, n=5; ACo: 5.2+/-0.2, n=5) between the experimental groups.",Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15300360/),,5.2,65935,DB00264,Metoprolol
,16029965,AUC,"In contrast, the AUC (ng h/mL) of alpha-hydroxymetoprolol isomers were higher to I'R [638.2(525.2-706.2) for 1'R2R and 659.6(580.4-698.1) for 1'R,2S, mean, (95%CI)] than to I'S products [58.3(47.4-66.1) for 1'S,2R and 57.1(44.7-67.9) for 1'S,2S, mean, (95%CI)].",Stereoselective analysis of metoprolol and its metabolites in rat plasma with application to oxidative metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029965/),[h·ng] / [ml],638.2,70726,DB00264,Metoprolol
,16029965,AUC,"In contrast, the AUC (ng h/mL) of alpha-hydroxymetoprolol isomers were higher to I'R [638.2(525.2-706.2) for 1'R2R and 659.6(580.4-698.1) for 1'R,2S, mean, (95%CI)] than to I'S products [58.3(47.4-66.1) for 1'S,2R and 57.1(44.7-67.9) for 1'S,2S, mean, (95%CI)].",Stereoselective analysis of metoprolol and its metabolites in rat plasma with application to oxidative metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029965/),[h·ng] / [ml],659.6,70727,DB00264,Metoprolol
,16029965,AUC,"In contrast, the AUC (ng h/mL) of alpha-hydroxymetoprolol isomers were higher to I'R [638.2(525.2-706.2) for 1'R2R and 659.6(580.4-698.1) for 1'R,2S, mean, (95%CI)] than to I'S products [58.3(47.4-66.1) for 1'S,2R and 57.1(44.7-67.9) for 1'S,2S, mean, (95%CI)].",Stereoselective analysis of metoprolol and its metabolites in rat plasma with application to oxidative metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029965/),[h·ng] / [ml],58.3,70728,DB00264,Metoprolol
,16029965,AUC,"In contrast, the AUC (ng h/mL) of alpha-hydroxymetoprolol isomers were higher to I'R [638.2(525.2-706.2) for 1'R2R and 659.6(580.4-698.1) for 1'R,2S, mean, (95%CI)] than to I'S products [58.3(47.4-66.1) for 1'S,2R and 57.1(44.7-67.9) for 1'S,2S, mean, (95%CI)].",Stereoselective analysis of metoprolol and its metabolites in rat plasma with application to oxidative metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029965/),[h·ng] / [ml],57.1,70729,DB00264,Metoprolol
,10423287,"maximum plasma concentration, C(max)","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[ng] / [ml],179.99,70730,DB00264,Metoprolol
,10423287,"maximum plasma concentration, C(max)","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[ng] / [ml],151.30,70731,DB00264,Metoprolol
,10423287,"area under the plasma concentration versus time curve, AUC(0-24)","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[h·ng] / [ml],929.85,70732,DB00264,Metoprolol
,10423287,"area under the plasma concentration versus time curve, AUC(0-24)","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[h·ng] / [ml],782.11,70733,DB00264,Metoprolol
,10423287,"apparent total clearance, Cl(T)/f","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[l] / [h·kg],1.70,70734,DB00264,Metoprolol
,10423287,"apparent total clearance, Cl(T)/f","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[l] / [h·kg],2.21,70735,DB00264,Metoprolol
,10423287,"apparent distribution volume, Vd/f","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[l] / [kg],10.51,70736,DB00264,Metoprolol
,10423287,"apparent distribution volume, Vd/f","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[l] / [kg],13.80,70737,DB00264,Metoprolol
,10423287,"renal clearance, Cl","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[l] / [kg],0.06,70738,DB00264,Metoprolol
,10423287,"renal clearance, Cl","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[l] / [kg],0.07,70739,DB00264,Metoprolol
,10824636,AUC,The AUC of paroxetine in subjects who were homozygous for CYP2D6*10B (666.4 +/- 169.4 ng/mL x h) was significantly greater than that of subjects who were homozygous for the wild type (194.5 +/- 55.9 ng/mL x h).,Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824636/),[ng] / [h·ml],666.4,73233,DB00264,Metoprolol
,10824636,AUC,The AUC of paroxetine in subjects who were homozygous for CYP2D6*10B (666.4 +/- 169.4 ng/mL x h) was significantly greater than that of subjects who were homozygous for the wild type (194.5 +/- 55.9 ng/mL x h).,Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824636/),[ng] / [h·ml],194.5,73234,DB00264,Metoprolol
,10824636,AUC,"Unexpectedly, the average AUC of subjects who were heterozygous for CYP2D6*10B was greater with wide variation (789.8 +/- 816.9 ng/mL x h) than that of subjects who were homozygous CYP2D6*10B/*10B mainly because of two atypical subjects whose metoprolol MR was not associated with the CYP2D6*10B genotype and who showed greater AUC and lower oral clearance than subjects with homozygous CYP2D6*10B.",Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824636/),[ng] / [h·ml],789.8,73235,DB00264,Metoprolol
,11968069,T(max),"The mean T(max) of metoprolol after the S, M, F (4.43, 4.00, 3.14 h, respectively) was found to be different ( P < 0.05) as compared to the OS (2.07 h).",Influence of input rate on the stereospecific and nonstereospecific first pass metabolism and pharmacokinetics of metoprolol extended release formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11968069/),h,4.43,73260,DB00264,Metoprolol
,11968069,T(max),"The mean T(max) of metoprolol after the S, M, F (4.43, 4.00, 3.14 h, respectively) was found to be different ( P < 0.05) as compared to the OS (2.07 h).",Influence of input rate on the stereospecific and nonstereospecific first pass metabolism and pharmacokinetics of metoprolol extended release formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11968069/),h,4.00,73261,DB00264,Metoprolol
,11968069,T(max),"The mean T(max) of metoprolol after the S, M, F (4.43, 4.00, 3.14 h, respectively) was found to be different ( P < 0.05) as compared to the OS (2.07 h).",Influence of input rate on the stereospecific and nonstereospecific first pass metabolism and pharmacokinetics of metoprolol extended release formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11968069/),h,3.14,73262,DB00264,Metoprolol
,11968069,T(max),"The mean T(max) of metoprolol after the S, M, F (4.43, 4.00, 3.14 h, respectively) was found to be different ( P < 0.05) as compared to the OS (2.07 h).",Influence of input rate on the stereospecific and nonstereospecific first pass metabolism and pharmacokinetics of metoprolol extended release formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11968069/),h,2.07,73263,DB00264,Metoprolol
less,26891872,IC50,"The ethyl acetate, alcoholic &amp; aqueous bark extracts of T. arjuna showed potent reversible non-competitive inhibition CYP2D enzyme in rat liver microsomes with IC50 values less than 40 μg/mL.",In Vitro CYP2D Inhibitory Effect and Influence on Pharmacokinetics and Pharmacodynamic Parameters of Metoprolol Succinate by Terminalia arjuna in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26891872/),[μg] / [ml],40,76815,DB00264,Metoprolol
,20044316,m/z,"The mass transitions monitored were m/z 426.3-->100.0, m/z 411.3-->100.0 and m/z 268.3-->116.1 for tiloronoxim, tilorone and the IS, respectively.","Performance of tiloronoxim and tilorone determination in human blood by HPLC-MS/MS: method validation, uncertainty assessment and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20044316/),,426.3,80601,DB00264,Metoprolol
,20044316,m/z,"The mass transitions monitored were m/z 426.3-->100.0, m/z 411.3-->100.0 and m/z 268.3-->116.1 for tiloronoxim, tilorone and the IS, respectively.","Performance of tiloronoxim and tilorone determination in human blood by HPLC-MS/MS: method validation, uncertainty assessment and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20044316/),,411.3,80602,DB00264,Metoprolol
,20044316,m/z,"The mass transitions monitored were m/z 426.3-->100.0, m/z 411.3-->100.0 and m/z 268.3-->116.1 for tiloronoxim, tilorone and the IS, respectively.","Performance of tiloronoxim and tilorone determination in human blood by HPLC-MS/MS: method validation, uncertainty assessment and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20044316/),,100.0,80603,DB00264,Metoprolol
,20044316,m/z,"The mass transitions monitored were m/z 426.3-->100.0, m/z 411.3-->100.0 and m/z 268.3-->116.1 for tiloronoxim, tilorone and the IS, respectively.","Performance of tiloronoxim and tilorone determination in human blood by HPLC-MS/MS: method validation, uncertainty assessment and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20044316/),,268.3,80604,DB00264,Metoprolol
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],378,80807,DB00264,Metoprolol
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],309,80808,DB00264,Metoprolol
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],66.7,80809,DB00264,Metoprolol
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],48,80810,DB00264,Metoprolol
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],42.9,80811,DB00264,Metoprolol
,2903820,oral bioavailability,"The oral bioavailability of bisoprolol is high (90%) and the drug has a long elimination half-life which allows once-daily administration; in addition, it is hepatically and renally cleared in equal proportions.","Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903820/),%,90,81252,DB00264,Metoprolol
,8748391,t1/2,"In addition, the t1/2 of the active moiety was prolonged (19 h in young subjects versus about 25 h in elderly and renal disease patients).","Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748391/),h,19,81649,DB00264,Metoprolol
,8748391,t1/2,"In addition, the t1/2 of the active moiety was prolonged (19 h in young subjects versus about 25 h in elderly and renal disease patients).","Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748391/),h,25,81650,DB00264,Metoprolol
,1848636,IC50,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).",Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1848636/),[ng] / [ml],72,82447,DB00264,Metoprolol
,1848636,IC50,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).",Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1848636/),[ng] / [ml],42,82448,DB00264,Metoprolol
,17418521,flow rate,"After alkalization with sodium hydroxide, the samples were extracted with ethyl acetate and separated by HPLC on a ZORBAX SB-C18 column with a mobile phase of 10 mM ammonium acetate buffer containing 0.1% formic acid-methanol (32:68, v/v) at a flow rate of 1 ml/min.",LC-ESI-MS method for the determination of bisoprolol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17418521/),[ml] / [min],1,82588,DB00264,Metoprolol
,8941022,hepatic extraction,The mean hepatic extraction of fluvastatin was 67% after the jejunal perfusion and 73% after the intravenous infusion.,Jejunal permeability and hepatic extraction of fluvastatin in humans. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941022/),%,67,88754,DB00264,Metoprolol
,8941022,hepatic extraction,The mean hepatic extraction of fluvastatin was 67% after the jejunal perfusion and 73% after the intravenous infusion.,Jejunal permeability and hepatic extraction of fluvastatin in humans. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941022/),%,73,88755,DB00264,Metoprolol
,8941022,half-life,The half-life of fluvastatin was approximately 60 minutes after both administration routes.,Jejunal permeability and hepatic extraction of fluvastatin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941022/),min,60,88756,DB00264,Metoprolol
,16238904,absolute oral bioavailability,"The absolute oral bioavailability of telithromycin is approximately 57%, which is unaffected by food intake.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),%,57,91339,DB00264,Metoprolol
,16238904,steady-state concentration,"At the recommended 800 mg once-daily oral dosing regimen, telithromycin reaches a steady-state concentration of approximately 2 microg/mL in plasma and has an elimination half-life of approximately 10 hours.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),[μg] / [ml],2,91340,DB00264,Metoprolol
,16238904,elimination half-life,"At the recommended 800 mg once-daily oral dosing regimen, telithromycin reaches a steady-state concentration of approximately 2 microg/mL in plasma and has an elimination half-life of approximately 10 hours.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),h,10,91341,DB00264,Metoprolol
,25364697,Area under the plasma concentration-time curve (AUC0-12),Area under the plasma concentration-time curve (AUC0-12) of metoprolol has significantly (P < 0.001) decreased by 9.8 times in the metoprolol and quercetin combination group (9434.65 ± 3525.02) when compared with AUC0-12 metoprolol of metoprolol-alone treated group (962.17 ± 242.81).,Quercetin declines plasma exposure of metoprolol tartrate in the rat model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364697/),,9434.65,92202,DB00264,Metoprolol
,25364697,AUC0-12,Area under the plasma concentration-time curve (AUC0-12) of metoprolol has significantly (P < 0.001) decreased by 9.8 times in the metoprolol and quercetin combination group (9434.65 ± 3525.02) when compared with AUC0-12 metoprolol of metoprolol-alone treated group (962.17 ± 242.81).,Quercetin declines plasma exposure of metoprolol tartrate in the rat model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364697/),,962.17,92203,DB00264,Metoprolol
,25364697,AUC0-∞,AUC0-∞ of metoprolol has significantly (P < 0.001) decreased by 14.9 times in the combination group (16670.79 ± 12129.06) in comparison to AUC0-∞ of metoprolol of metoprolol-alone treated group (1113.68 ± 441.83).,Quercetin declines plasma exposure of metoprolol tartrate in the rat model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364697/),,16670.79,92204,DB00264,Metoprolol
,25364697,AUC0-∞,AUC0-∞ of metoprolol has significantly (P < 0.001) decreased by 14.9 times in the combination group (16670.79 ± 12129.06) in comparison to AUC0-∞ of metoprolol of metoprolol-alone treated group (1113.68 ± 441.83).,Quercetin declines plasma exposure of metoprolol tartrate in the rat model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364697/),,1113.68,92205,DB00264,Metoprolol
,17333158,AUC(0-12),"The bioavailability of the metoprolol was significantly less on the first postoperative day, with AUC(0-12) values ranging from 0.7 to 17.1 (median: 7.2) mg min/L, than on the preoperative day, with AUC(0-12) values of 5.1-26.7 (12.6) mg min/L; however, it returned to the preoperative values on the third postoperative day, with AUC(0-12) values of 3.5-25.2 (15.2) mg min/L.",Does coronary artery bypass surgery affect metoprolol bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333158/),[mg·min] / [l],0.7 to 17.1,93425,DB00264,Metoprolol
,17333158,AUC(0-12),"The bioavailability of the metoprolol was significantly less on the first postoperative day, with AUC(0-12) values ranging from 0.7 to 17.1 (median: 7.2) mg min/L, than on the preoperative day, with AUC(0-12) values of 5.1-26.7 (12.6) mg min/L; however, it returned to the preoperative values on the third postoperative day, with AUC(0-12) values of 3.5-25.2 (15.2) mg min/L.",Does coronary artery bypass surgery affect metoprolol bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333158/),[mg·min] / [l],7.2,93426,DB00264,Metoprolol
,17333158,AUC(0-12),"The bioavailability of the metoprolol was significantly less on the first postoperative day, with AUC(0-12) values ranging from 0.7 to 17.1 (median: 7.2) mg min/L, than on the preoperative day, with AUC(0-12) values of 5.1-26.7 (12.6) mg min/L; however, it returned to the preoperative values on the third postoperative day, with AUC(0-12) values of 3.5-25.2 (15.2) mg min/L.",Does coronary artery bypass surgery affect metoprolol bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333158/),[mg·min] / [l],5.1-26.7,93427,DB00264,Metoprolol
,17333158,AUC(0-12),"The bioavailability of the metoprolol was significantly less on the first postoperative day, with AUC(0-12) values ranging from 0.7 to 17.1 (median: 7.2) mg min/L, than on the preoperative day, with AUC(0-12) values of 5.1-26.7 (12.6) mg min/L; however, it returned to the preoperative values on the third postoperative day, with AUC(0-12) values of 3.5-25.2 (15.2) mg min/L.",Does coronary artery bypass surgery affect metoprolol bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333158/),[mg·min] / [l],3.5-25.2,93428,DB00264,Metoprolol
,17333158,C(max),"Similar changes were observed in C(max) values: preoperative C(max) ranged between 0.026 and 0.123 (0.060) mg/L, on the first postoperative day, the C(max) ranged between 0.003 and 0.093 (0.025) mg/L, and on the third postoperative day, the C(max) ranged between 0.009 and 0.136 (0.061) mg/L.",Does coronary artery bypass surgery affect metoprolol bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333158/),[mg] / [l],0.026 and 0.123,93429,DB00264,Metoprolol
,17333158,C(max),"Similar changes were observed in C(max) values: preoperative C(max) ranged between 0.026 and 0.123 (0.060) mg/L, on the first postoperative day, the C(max) ranged between 0.003 and 0.093 (0.025) mg/L, and on the third postoperative day, the C(max) ranged between 0.009 and 0.136 (0.061) mg/L.",Does coronary artery bypass surgery affect metoprolol bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333158/),[mg] / [l],0.003 and 0.093,93430,DB00264,Metoprolol
,17333158,C(max),"Similar changes were observed in C(max) values: preoperative C(max) ranged between 0.026 and 0.123 (0.060) mg/L, on the first postoperative day, the C(max) ranged between 0.003 and 0.093 (0.025) mg/L, and on the third postoperative day, the C(max) ranged between 0.009 and 0.136 (0.061) mg/L.",Does coronary artery bypass surgery affect metoprolol bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17333158/),[mg] / [l],0.009 and 0.136,93431,DB00264,Metoprolol
,10915931,oral clearance,"The oral clearance after single dose was 1.99+/-0.87 and 2. 26+/-0.85 ml min(-1) kg(-1) for R- and S-MET, respectively.",Pharmacokinetics of metoprolol enantiomers following single and multiple administration of racemate in rat. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10915931/),[ml] / [kg·min],1.99,94954,DB00264,Metoprolol
,10915931,oral clearance,"The oral clearance after single dose was 1.99+/-0.87 and 2. 26+/-0.85 ml min(-1) kg(-1) for R- and S-MET, respectively.",Pharmacokinetics of metoprolol enantiomers following single and multiple administration of racemate in rat. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10915931/),[ml] / [kg·min],2. 26,94955,DB00264,Metoprolol
,10915931,elimination half-lives,"The corresponding values for the elimination half-lives were approximately 35 and 33 min after single and multiple dose administration for both enantiomers, respectively.",Pharmacokinetics of metoprolol enantiomers following single and multiple administration of racemate in rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10915931/),min,35,94956,DB00264,Metoprolol
,10915931,elimination half-lives,"The corresponding values for the elimination half-lives were approximately 35 and 33 min after single and multiple dose administration for both enantiomers, respectively.",Pharmacokinetics of metoprolol enantiomers following single and multiple administration of racemate in rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10915931/),min,33,94957,DB00264,Metoprolol
,22391600,flow rate,"An Ultimate XB-C₁₈ column (150 × 2.1 mm ID, 5 μm) was used for separation, with methanol-water containing 0.2% formic acid (65:35, v/v) as the mobile phase at a flow rate of 0.2 mL/min.",Rapid and sensitive LC-MS/MS method for the determination of metoprolol in Beagle dog plasma with a simple protein precipitation treatment and its pharmacokinetic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22391600/),[ml] / [min],0.2,100378,DB00264,Metoprolol
,22391600,m/z,"Monitoring ions of MP and internal standard (hydroxypioglitazone) were m/z 268.1/115.6 and m/z 373.1/150.2, respectively.",Rapid and sensitive LC-MS/MS method for the determination of metoprolol in Beagle dog plasma with a simple protein precipitation treatment and its pharmacokinetic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22391600/),,268.1,100379,DB00264,Metoprolol
,22391600,m/z,"Monitoring ions of MP and internal standard (hydroxypioglitazone) were m/z 268.1/115.6 and m/z 373.1/150.2, respectively.",Rapid and sensitive LC-MS/MS method for the determination of metoprolol in Beagle dog plasma with a simple protein precipitation treatment and its pharmacokinetic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22391600/),,115.6,100380,DB00264,Metoprolol
,22391600,m/z,"Monitoring ions of MP and internal standard (hydroxypioglitazone) were m/z 268.1/115.6 and m/z 373.1/150.2, respectively.",Rapid and sensitive LC-MS/MS method for the determination of metoprolol in Beagle dog plasma with a simple protein precipitation treatment and its pharmacokinetic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22391600/),,373.1,100381,DB00264,Metoprolol
,22391600,m/z,"Monitoring ions of MP and internal standard (hydroxypioglitazone) were m/z 268.1/115.6 and m/z 373.1/150.2, respectively.",Rapid and sensitive LC-MS/MS method for the determination of metoprolol in Beagle dog plasma with a simple protein precipitation treatment and its pharmacokinetic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22391600/),,150.2,100382,DB00264,Metoprolol
,22391600,AUC(0-t),"The AUC(0-t), T(max) and C(max) were respectively 919.88 ± 195.67 μg/L·h, 0.96 ± 0.33 h, 349.12 ± 78.04 ng/mL.",Rapid and sensitive LC-MS/MS method for the determination of metoprolol in Beagle dog plasma with a simple protein precipitation treatment and its pharmacokinetic applications. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22391600/),[μg] / [h·l],919.88,100383,DB00264,Metoprolol
,22391600,T(max),"The AUC(0-t), T(max) and C(max) were respectively 919.88 ± 195.67 μg/L·h, 0.96 ± 0.33 h, 349.12 ± 78.04 ng/mL.",Rapid and sensitive LC-MS/MS method for the determination of metoprolol in Beagle dog plasma with a simple protein precipitation treatment and its pharmacokinetic applications. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22391600/),h,0.96,100384,DB00264,Metoprolol
,22391600,C(max),"The AUC(0-t), T(max) and C(max) were respectively 919.88 ± 195.67 μg/L·h, 0.96 ± 0.33 h, 349.12 ± 78.04 ng/mL.",Rapid and sensitive LC-MS/MS method for the determination of metoprolol in Beagle dog plasma with a simple protein precipitation treatment and its pharmacokinetic applications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22391600/),[ng] / [ml],349.12,100385,DB00264,Metoprolol
,19477256,absolute bioavailability,Nasal administration of Amioca/Carbopol 974P powders without heat treatment resulted in an absolute bioavailability in rabbits of 8.2+/-3.0% for insulin.,Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,8.2,102369,DB00264,Metoprolol
,19477256,bioavailability,"Due to the difference in water-absorbing capacity (which opened the tight junctions of the nasal mucosa), elasticity and plasticity (which reduced mucociliairy clearance and prolonged residence time) heat treatment at 120 degrees C improved the bioavailability: 26.4+/-21.9, 36.5+/-11.0 and 19.3+/-17.3% after heat treatment during 30 min, 1 h and 4 h, respectively.",Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,26.4,102370,DB00264,Metoprolol
,19477256,bioavailability,"Due to the difference in water-absorbing capacity (which opened the tight junctions of the nasal mucosa), elasticity and plasticity (which reduced mucociliairy clearance and prolonged residence time) heat treatment at 120 degrees C improved the bioavailability: 26.4+/-21.9, 36.5+/-11.0 and 19.3+/-17.3% after heat treatment during 30 min, 1 h and 4 h, respectively.",Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,36.5,102371,DB00264,Metoprolol
,19477256,bioavailability,"Due to the difference in water-absorbing capacity (which opened the tight junctions of the nasal mucosa), elasticity and plasticity (which reduced mucociliairy clearance and prolonged residence time) heat treatment at 120 degrees C improved the bioavailability: 26.4+/-21.9, 36.5+/-11.0 and 19.3+/-17.3% after heat treatment during 30 min, 1 h and 4 h, respectively.",Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,19.3,102372,DB00264,Metoprolol
,12852442,absorption half-life,"The absorption half-life of the investigated drugs ranged from 2 to 59 min, and the extent of absorption from 21 to 94% in 2 h in the isolated perfused rat lung model.",Drug absorption from the isolated perfused rat lung--correlations with drug physicochemical properties and epithelial permeability. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852442/),min,2 to 59,102577,DB00264,Metoprolol
,2455148,maximum nifedipine plasma concentration,"The maximum nifedipine plasma concentration after the capsule was 257 ng/ml compared with 50 ng/ml for the tablet, and the time of maximum concentration was significantly earlier for the capsule.",Comparative pharmacokinetics and antihypertensive effects of the nifedipine tablet and capsule. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2455148/),[ng] / [ml],257,102745,DB00264,Metoprolol
,2455148,maximum nifedipine plasma concentration,"The maximum nifedipine plasma concentration after the capsule was 257 ng/ml compared with 50 ng/ml for the tablet, and the time of maximum concentration was significantly earlier for the capsule.",Comparative pharmacokinetics and antihypertensive effects of the nifedipine tablet and capsule. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2455148/),[ng] / [ml],50,102746,DB00264,Metoprolol
,24018320,flow rate,The analysis was performed in less than 16min with a flow rate of 0.8mL/min.,Determination of metoprolol and its two metabolites in human plasma and urine by high performance liquid chromatography with fluorescence detection and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24018320/),[ml] / [min],0.8,104394,DB00264,Metoprolol
,24018320,LOQ,"The LOQ were 5.0 and 2.5ng/mL for plasma and urine, respectively.",Determination of metoprolol and its two metabolites in human plasma and urine by high performance liquid chromatography with fluorescence detection and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24018320/),[ng] / [ml],5.0,104395,DB00264,Metoprolol
,24018320,LOQ,"The LOQ were 5.0 and 2.5ng/mL for plasma and urine, respectively.",Determination of metoprolol and its two metabolites in human plasma and urine by high performance liquid chromatography with fluorescence detection and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24018320/),[ng] / [ml],2.5,104396,DB00264,Metoprolol
more,24018320,extraction recoveries,The extraction recoveries were found to be more than 86.91% both in plasma and urine.,Determination of metoprolol and its two metabolites in human plasma and urine by high performance liquid chromatography with fluorescence detection and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24018320/),%,86.91,104397,DB00264,Metoprolol
,10824625,inhibitory constant,"In vitro, diphenhydramine was a potent competitive inhibitor of metoprolol alpha-hydroxylation, exhibiting an inhibitory constant of 2 micromol/L and increasing the Michaelis-Menten constant of metoprolol sixfold.",Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824625/),[μM] / [l],2,105802,DB00264,Metoprolol
,11782853,peak plasma levels,Metoprolol IR 50 mg produced peak plasma levels comparable to those observed for CR/XL 200 mg (285 v 263 nmol/L).,Dose-related effects of metoprolol on heart rate and pharmacokinetics in heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782853/),[nM] / [l],285,105989,DB00264,Metoprolol
,11782853,peak plasma levels,Metoprolol IR 50 mg produced peak plasma levels comparable to those observed for CR/XL 200 mg (285 v 263 nmol/L).,Dose-related effects of metoprolol on heart rate and pharmacokinetics in heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782853/),[nM] / [l],263,105990,DB00264,Metoprolol
,520399,time to reach peak concentration,"Food intake significantly shortened the time to reach peak concentration (2.7 h vs 1.5 h), but caused a significant reduction in AUC values, the mean decrease being 20%.",Food-induced reduction in bioavailability of atenolol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/520399/),h,2.7,106126,DB00264,Metoprolol
,520399,time to reach peak concentration,"Food intake significantly shortened the time to reach peak concentration (2.7 h vs 1.5 h), but caused a significant reduction in AUC values, the mean decrease being 20%.",Food-induced reduction in bioavailability of atenolol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/520399/),h,1.5,106127,DB00264,Metoprolol
,27536063,absolute bioavailability,"In addition, the absolute bioavailability of the drug (ie, relative to intravenous administration) following sublingual administration was found to be significantly higher (91.06%±13.28%), as compared with that after oral tablet administration (39.37%±11.4%).",Sublingual fast dissolving niosomal films for enhanced bioavailability and prolonged effect of metoprolol tartrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536063/),%,91.06,106966,DB00264,Metoprolol
,27536063,absolute bioavailability,"In addition, the absolute bioavailability of the drug (ie, relative to intravenous administration) following sublingual administration was found to be significantly higher (91.06%±13.28%), as compared with that after oral tablet administration (39.37%±11.4%).",Sublingual fast dissolving niosomal films for enhanced bioavailability and prolonged effect of metoprolol tartrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536063/),%,39.37,106967,DB00264,Metoprolol
,1856430,Peak plasma concentration,"Peak plasma concentration was significantly higher after intravenous infusion of metoprolol (1,188 +/- 503 nmol/liter) than after coronary venous infusion (417 +/- 155 nmol/liter; p less than 0.001).",Pharmacokinetic analysis of coronary venous retroinfusion: a comparison with anterograde coronary artery drug administration using metoprolol as a tracer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1856430/),[nM] / [l],"1,188",107524,DB00264,Metoprolol
,1856430,Peak plasma concentration,"Peak plasma concentration was significantly higher after intravenous infusion of metoprolol (1,188 +/- 503 nmol/liter) than after coronary venous infusion (417 +/- 155 nmol/liter; p less than 0.001).",Pharmacokinetic analysis of coronary venous retroinfusion: a comparison with anterograde coronary artery drug administration using metoprolol as a tracer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1856430/),[nM] / [l],417,107525,DB00264,Metoprolol
,17331818,run time,"The mobile phase consisted of water-acetonitrile and formic acid (55/45/0.048, v/v/%) and the run time was 3 min.",Simple and rapid method determination for metformin in human plasma using high performance liquid chromatography tandem mass spectrometry: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331818/),min,3,108202,DB00264,Metoprolol
,17331818,C(max),The method was applied to determine the pharmacokinetic parameters: C(max) (1667.25 ng/mL) and T(max) (3.89 h).,Simple and rapid method determination for metformin in human plasma using high performance liquid chromatography tandem mass spectrometry: application to pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331818/),[ng] / [ml],1667.25,108203,DB00264,Metoprolol
,17331818,T(max),The method was applied to determine the pharmacokinetic parameters: C(max) (1667.25 ng/mL) and T(max) (3.89 h).,Simple and rapid method determination for metformin in human plasma using high performance liquid chromatography tandem mass spectrometry: application to pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331818/),h,3.89,108204,DB00264,Metoprolol
,20079994,flow rate,"Sample preparation by liquid-liquid extraction with diethyl ether-dichloromethane (60:40, v/v) was followed by chromatography on a Venusil MP-C18 column using methanol-ammonium acetate (10mM)-formic acid (pH 3.4) (50:50:0.05, v/v/v) at a flow rate of 0.8mL/min.",Simultaneous quantitation of hydrochlorothiazide and metoprolol in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079994/),[ml] / [min],0.8,108680,DB00264,Metoprolol
,4005125,initial in,The initial in vitro release rate for both Oros preparations was 19 mg/h but they contained 190 or 285 mg of metoprolol fumarate.,Osmotically controlled-delivery of metoprolol in man: in vivo performance of Oros systems with different durations of drug release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4005125/),[mg] / [h],19,110892,DB00264,Metoprolol
,26187926,flow rate,"The separation was performed on an Agilent HC-C18 column (4.6 × 250 mm, 5 µm) at a flow rate of 1.0 mL/min, using methanol-water containing 0.1% formic acid (39:61, v/v) as mobile phase, and total run time was 8.5 min.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),[ml] / [min],1.0,116281,DB00264,Metoprolol
,26187926,total run time,"The separation was performed on an Agilent HC-C18 column (4.6 × 250 mm, 5 µm) at a flow rate of 1.0 mL/min, using methanol-water containing 0.1% formic acid (39:61, v/v) as mobile phase, and total run time was 8.5 min.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),min,8.5,116282,DB00264,Metoprolol
,26187926,m/,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,130.1,116283,DB00264,Metoprolol
,26187926,m/,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,60.2,116284,DB00264,Metoprolol
,26187926,m/z,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,268.2,116285,DB00264,Metoprolol
,26187926,m/z,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,116.1,116286,DB00264,Metoprolol
,26187926,m/,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,284.2,116287,DB00264,Metoprolol
,26187926,m/z,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,254.2,116288,DB00264,Metoprolol
,26187926,m/z,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,152.3,116289,DB00264,Metoprolol
,26187926,m/z,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,110.1,116290,DB00264,Metoprolol
,31442620,AUC,"After exposure to EPP-AF®, it was observed decrease in the AUC0-∞ of fexofenadine, caffeine and losartan of approximately 18% (62.20 × 51.00 h.ng/mL), 8% (1085 × 999 h.ng/mL) and 13% (9.01 × 7.86 h.ng/mL), respectively, with all 90% CIs within the equivalence range of 0.80-1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),,62,116459,DB00264,Metoprolol
,31442620,AUC0-∞,"On the other hand, omeprazole and midazolam exhibited an increase in AUC0-∞ of, respectively, approximately 18% (18.90 × 22.30 h.ng/mL) and 14% (1.25 × 1.43 h.ng/mL), with the upper bounds of 90% CIs slightly above 1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),[h·ng] / [ml],18,116460,DB00264,Metoprolol
,31442620,AUC0-∞,"On the other hand, omeprazole and midazolam exhibited an increase in AUC0-∞ of, respectively, approximately 18% (18.90 × 22.30 h.ng/mL) and 14% (1.25 × 1.43 h.ng/mL), with the upper bounds of 90% CIs slightly above 1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),[h·ng] / [ml],1.,116461,DB00264,Metoprolol
,16473430,AUC,"AUC and MRT values following administration of SR granules of MO with a coating layer containing 8% of CP to beagle dogs were 191 ng h/mL and 10.6 h respectively, while those following SR granules of MO with a coating layer containing 1% of CP to beagle dogs were 86.4 ng h/mL and 5.86 h, respectively.",Development of an oral sustained release drug delivery system utilizing pH-dependent swelling of carboxyvinyl polymer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16473430/),[h·ng] / [ml],191,118024,DB00264,Metoprolol
,16473430,AUC,"AUC and MRT values following administration of SR granules of MO with a coating layer containing 8% of CP to beagle dogs were 191 ng h/mL and 10.6 h respectively, while those following SR granules of MO with a coating layer containing 1% of CP to beagle dogs were 86.4 ng h/mL and 5.86 h, respectively.",Development of an oral sustained release drug delivery system utilizing pH-dependent swelling of carboxyvinyl polymer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16473430/),[h·ng] / [ml],86.4,118025,DB00264,Metoprolol
,16473430,MRT,"AUC and MRT values following administration of SR granules of MO with a coating layer containing 8% of CP to beagle dogs were 191 ng h/mL and 10.6 h respectively, while those following SR granules of MO with a coating layer containing 1% of CP to beagle dogs were 86.4 ng h/mL and 5.86 h, respectively.",Development of an oral sustained release drug delivery system utilizing pH-dependent swelling of carboxyvinyl polymer. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16473430/),h,10.6,118026,DB00264,Metoprolol
,16473430,MRT,"AUC and MRT values following administration of SR granules of MO with a coating layer containing 8% of CP to beagle dogs were 191 ng h/mL and 10.6 h respectively, while those following SR granules of MO with a coating layer containing 1% of CP to beagle dogs were 86.4 ng h/mL and 5.86 h, respectively.",Development of an oral sustained release drug delivery system utilizing pH-dependent swelling of carboxyvinyl polymer. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16473430/),h,5.86,118027,DB00264,Metoprolol
,1418033,Cmax,"1. Mean +/- S.E. values of Cmax, tmax and AUC0-24 after oral administration of slow-release metoprolol tablets to 75 healthy male volunteers and 15 arrhythmic patients were 95.3 +/- 6.6 ng/ml, 4.4 +/- 0.2 h and 1000.4 +/- 70.9 ng.h/ml, respectively.",Variation of pharmacokinetics after oral administration of slow-release metoprolol tablets and pharmacogenetic considerations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418033/),[ng] / [ml],95.3,118438,DB00264,Metoprolol
,1418033,tmax,"1. Mean +/- S.E. values of Cmax, tmax and AUC0-24 after oral administration of slow-release metoprolol tablets to 75 healthy male volunteers and 15 arrhythmic patients were 95.3 +/- 6.6 ng/ml, 4.4 +/- 0.2 h and 1000.4 +/- 70.9 ng.h/ml, respectively.",Variation of pharmacokinetics after oral administration of slow-release metoprolol tablets and pharmacogenetic considerations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418033/),h,4.4,118439,DB00264,Metoprolol
,1418033,AUC0-24,"1. Mean +/- S.E. values of Cmax, tmax and AUC0-24 after oral administration of slow-release metoprolol tablets to 75 healthy male volunteers and 15 arrhythmic patients were 95.3 +/- 6.6 ng/ml, 4.4 +/- 0.2 h and 1000.4 +/- 70.9 ng.h/ml, respectively.",Variation of pharmacokinetics after oral administration of slow-release metoprolol tablets and pharmacogenetic considerations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418033/),[h·ng] / [ml],1000.4,118440,DB00264,Metoprolol
,6707925,Cls,The Cls [dose i.v./area under the blood concentration vs. time curve in the femoral vein (AUCs)] varied between 27 and 32 ml X kg-1 X min-1.,Comparison of different clearance estimates for metoprolol in the rhesus monkey. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707925/),[ml] / [kg·min],27 and 32,118740,DB00264,Metoprolol
,6707925,area under the blood concentration vs. time curve,The Cls [dose i.v./area under the blood concentration vs. time curve in the femoral vein (AUCs)] varied between 27 and 32 ml X kg-1 X min-1.,Comparison of different clearance estimates for metoprolol in the rhesus monkey. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707925/),[ml] / [kg·min],27 and 32,118741,DB00264,Metoprolol
,6707925,Clo (doseo/AUCs),"As expected, the Clo (doseo/AUCs) was considerably higher and ranged from 89 to 147 ml X kg-1 X min-1.",Comparison of different clearance estimates for metoprolol in the rhesus monkey. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707925/),[ml] / [kg·min],89 to 147,118742,DB00264,Metoprolol
,6707925,Clo,The Cli (dosei.v./AUChv) was in the same range as Clo (46-163 ml X kg-1 X min-1).,Comparison of different clearance estimates for metoprolol in the rhesus monkey. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707925/),[ml] / [kg·min],46-163,118743,DB00264,Metoprolol
,6707925,oral availability,The determined oral availability was 19 to 31% with a mean of 25.(ABSTRACT TRUNCATED AT 250 WORDS),Comparison of different clearance estimates for metoprolol in the rhesus monkey. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707925/),,25,118744,DB00264,Metoprolol
,15484221,recovery,"Metoprolol recovery was determined at 73.0 +/- 20.5%, and the limit of quantitation was 2.4 ng/mL.",HPLC quantification of metoprolol with solid-phase extraction for the drug monitoring of pediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15484221/),%,73.0,125777,DB00264,Metoprolol
,11151741,trough-to-peak ratios (T:P),"The trough-to-peak ratios (T:P) were 75% and 79% for the systolic BP and 70% and 70% for the diastolic BP for the free and fixed combinations, respectively.",The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11151741/),%,75,130062,DB00264,Metoprolol
,11151741,trough-to-peak ratios (T:P),"The trough-to-peak ratios (T:P) were 75% and 79% for the systolic BP and 70% and 70% for the diastolic BP for the free and fixed combinations, respectively.",The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11151741/),%,79,130063,DB00264,Metoprolol
,11151741,trough-to-peak ratios (T:P),"The trough-to-peak ratios (T:P) were 75% and 79% for the systolic BP and 70% and 70% for the diastolic BP for the free and fixed combinations, respectively.",The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11151741/),%,70,130064,DB00264,Metoprolol
,15848051,C(max),The pulsatile drug delivery capsule caused two defined C(max) values for each dose between 1-1.75 and 2.5-3.5h.,"Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848051/),h,1-1.75,130123,DB00264,Metoprolol
,15848051,C(max),The pulsatile drug delivery capsule caused two defined C(max) values for each dose between 1-1.75 and 2.5-3.5h.,"Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848051/),h,2.5-3.5,130124,DB00264,Metoprolol
,21877256,elimination half-life,"With IP administration, the elimination half-life of metoprolol in pericardial fluid was 14.4 min with negligible accumulations in the plasma, whereas with IV delivery, the elimination half-life in plasma was 11.1 min with negligible amounts found in the pericardial fluid.",Cardiac responses to the intrapericardial delivery of metoprolol: targeted delivery compared to intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877256/),min,14.4,132284,DB00264,Metoprolol
,21877256,elimination half-life,"With IP administration, the elimination half-life of metoprolol in pericardial fluid was 14.4 min with negligible accumulations in the plasma, whereas with IV delivery, the elimination half-life in plasma was 11.1 min with negligible amounts found in the pericardial fluid.",Cardiac responses to the intrapericardial delivery of metoprolol: targeted delivery compared to intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877256/),min,11.1,132285,DB00264,Metoprolol
,6839004,renal clearance,"In contrast, mean peak plasma levels and AUC for atenolol were significantly lower, both by about 40 per cent, during infectious disease compared to the healthy state (p less than 0.05), where as renal clearance of atenolol slightly increased from 110.8 +/- 14.7 ml min-1 in the healthy state to 128 +/- 21.6 ml min-1, when the ESR's were elevated.",Influence of inflammatory disease on the clinical pharmacokinetics of atenolol and metoprolol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6839004/),[ml] / [min],110.8,133340,DB00264,Metoprolol
,6839004,renal clearance,"In contrast, mean peak plasma levels and AUC for atenolol were significantly lower, both by about 40 per cent, during infectious disease compared to the healthy state (p less than 0.05), where as renal clearance of atenolol slightly increased from 110.8 +/- 14.7 ml min-1 in the healthy state to 128 +/- 21.6 ml min-1, when the ESR's were elevated.",Influence of inflammatory disease on the clinical pharmacokinetics of atenolol and metoprolol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6839004/),[ml] / [min],128,133341,DB00264,Metoprolol
,6839004,elimination half-life,"The elimination half-life of atenolol, about 10 h, was not affected by the health status of the subjects.",Influence of inflammatory disease on the clinical pharmacokinetics of atenolol and metoprolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6839004/),h,10,133342,DB00264,Metoprolol
,18300480,relative bioavailability,The relative bioavailability of felodipine and metoprolol were 275.37% and 189.76% versus oral administration respectively.,[Preparation of transdermal drug delivery system of felodipine-metoprolol and its bioavailability in rabbits]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18300480/),%,275.37,134124,DB00264,Metoprolol
,18300480,relative bioavailability,The relative bioavailability of felodipine and metoprolol were 275.37% and 189.76% versus oral administration respectively.,[Preparation of transdermal drug delivery system of felodipine-metoprolol and its bioavailability in rabbits]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18300480/),%,189.76,134125,DB00264,Metoprolol
,2308905,oral bioavailability,The oral bioavailability of metoprolol was lower (6-22%) during pregnancy than in non-pregnancy (9-49%).,The rhesus monkey as a model for studies of pregnancy induced changes in metoprolol metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2308905/),%,6-22,135198,DB00264,Metoprolol
,2308905,oral bioavailability,The oral bioavailability of metoprolol was lower (6-22%) during pregnancy than in non-pregnancy (9-49%).,The rhesus monkey as a model for studies of pregnancy induced changes in metoprolol metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2308905/),%,9-49,135199,DB00264,Metoprolol
,23208431,Bioavailabilities,"Bioavailabilities were approximately 80% for caffeine and warfarin, but less than 10% for omeprazole, metoprolol, and midazolam.","Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208431/),%,80,137185,DB00264,Metoprolol
less,23208431,Bioavailabilities,"Bioavailabilities were approximately 80% for caffeine and warfarin, but less than 10% for omeprazole, metoprolol, and midazolam.","Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208431/),%,10,137186,DB00264,Metoprolol
,24648255,flow rate,"Chromatographic separation was performed on a Luna CN column with an isocratic mobile phase consisting of distilled water and methanol containing 0.1% formic acid (60:40, v/v) at a flow rate of 0.3 mL/min.","Simultaneous determination of metoprolol and its metabolites, α-hydroxymetoprolol and O-desmethylmetoprolol, in human plasma by liquid chromatography with tandem mass spectrometry: Application to the pharmacokinetics of metoprolol associated with CYP2D6 genotypes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648255/),[ml] / [min],0.3,137959,DB00264,Metoprolol
,24648255,total run time,The total run time was 3.0 min per sample.,"Simultaneous determination of metoprolol and its metabolites, α-hydroxymetoprolol and O-desmethylmetoprolol, in human plasma by liquid chromatography with tandem mass spectrometry: Application to the pharmacokinetics of metoprolol associated with CYP2D6 genotypes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648255/),[min] / [sample],3.0,137960,DB00264,Metoprolol
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,33.1,139253,DB00264,Metoprolol
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,31.7,139254,DB00264,Metoprolol
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,89.0,139255,DB00264,Metoprolol
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,86.6,139256,DB00264,Metoprolol
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,99.2,139257,DB00264,Metoprolol
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,99.0,139258,DB00264,Metoprolol
,3327676,elimination half-life,The mean elimination half-life of felodipine is approximately 25h.,Clinical pharmacokinetics of felodipine. A summary. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327676/),h,25,140911,DB00264,Metoprolol
,3327676,volume of distribution,"The volume of distribution of felodipine is about 10 L/kg, implying that less than 1% of the amount of drug in the body is localised in the blood.",Clinical pharmacokinetics of felodipine. A summary. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327676/),[l] / [kg],10,140912,DB00264,Metoprolol
,3327676,total clearance from the blood,"Mean total clearance from the blood is 1 to 1.5 L/min and, therefore, felodipine is considered a high clearance drug.",Clinical pharmacokinetics of felodipine. A summary. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327676/),[l] / [min],1 to 1.5,140913,DB00264,Metoprolol
,2312776,Cmax,"The plasma concentration-time profile following metoprolol CR/ZOK 50 mg administration was more even compared to conventional metoprolol tablets, with significantly lower Cmax (mean: 71 vs 221 nmol/L) and significantly higher Cmin (mean: 39 vs 6 nmol/L) for the CR/ZOK formulation.",Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312776/),[nM] / [l],71,141095,DB00264,Metoprolol
,2312776,Cmax,"The plasma concentration-time profile following metoprolol CR/ZOK 50 mg administration was more even compared to conventional metoprolol tablets, with significantly lower Cmax (mean: 71 vs 221 nmol/L) and significantly higher Cmin (mean: 39 vs 6 nmol/L) for the CR/ZOK formulation.",Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312776/),[nM] / [l],221,141096,DB00264,Metoprolol
,2312776,Cmin,"The plasma concentration-time profile following metoprolol CR/ZOK 50 mg administration was more even compared to conventional metoprolol tablets, with significantly lower Cmax (mean: 71 vs 221 nmol/L) and significantly higher Cmin (mean: 39 vs 6 nmol/L) for the CR/ZOK formulation.",Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312776/),[nM] / [l],39,141097,DB00264,Metoprolol
,2312776,Cmin,"The plasma concentration-time profile following metoprolol CR/ZOK 50 mg administration was more even compared to conventional metoprolol tablets, with significantly lower Cmax (mean: 71 vs 221 nmol/L) and significantly higher Cmin (mean: 39 vs 6 nmol/L) for the CR/ZOK formulation.",Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312776/),[nM] / [l],6,141098,DB00264,Metoprolol
,2312776,systemic bioavailability,"There was, however, no difference in systemic bioavailability between the two metoprolol formulations (90% confidence limits: 86-106%).",Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312776/),%,86-106,141099,DB00264,Metoprolol
,2312776,Emax,The beta 1-blockade was also more even after metoprolol CR/ZOK 50 mg compared to conventional tablets with a significantly lower Emax (mean: 14 vs 19%) and higher Emin (mean: 9 vs 0%) for CR/ZOK.,Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312776/),%,14,141100,DB00264,Metoprolol
,2312776,Emax,The beta 1-blockade was also more even after metoprolol CR/ZOK 50 mg compared to conventional tablets with a significantly lower Emax (mean: 14 vs 19%) and higher Emin (mean: 9 vs 0%) for CR/ZOK.,Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312776/),%,19,141101,DB00264,Metoprolol
,2312776,Emin,The beta 1-blockade was also more even after metoprolol CR/ZOK 50 mg compared to conventional tablets with a significantly lower Emax (mean: 14 vs 19%) and higher Emin (mean: 9 vs 0%) for CR/ZOK.,Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312776/),%,9,141102,DB00264,Metoprolol
,2312776,Emin,The beta 1-blockade was also more even after metoprolol CR/ZOK 50 mg compared to conventional tablets with a significantly lower Emax (mean: 14 vs 19%) and higher Emin (mean: 9 vs 0%) for CR/ZOK.,Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312776/),%,0,141103,DB00264,Metoprolol
,33799884,terminal half-life,"After an intravenous injection at a dose range of 0.5-5 mg/kg, the terminal half-life (i.e., 2.54-2.80 h), systemic clearance (i.e., 691-865 mL/h/kg), and steady state volume of distribution (i.e., 2040-3500 mL/kg) of supinoxin remained unchanged, suggesting dose-independent (i.e., dose-proportional) pharmacokinetics for the dose ranges studied.",Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33799884/),h,2.54-2.80,141851,DB00264,Metoprolol
,33799884,systemic clearance,"After an intravenous injection at a dose range of 0.5-5 mg/kg, the terminal half-life (i.e., 2.54-2.80 h), systemic clearance (i.e., 691-865 mL/h/kg), and steady state volume of distribution (i.e., 2040-3500 mL/kg) of supinoxin remained unchanged, suggesting dose-independent (i.e., dose-proportional) pharmacokinetics for the dose ranges studied.",Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33799884/),[ml] / [h·kg],691-865,141852,DB00264,Metoprolol
,33799884,steady state volume of distribution,"After an intravenous injection at a dose range of 0.5-5 mg/kg, the terminal half-life (i.e., 2.54-2.80 h), systemic clearance (i.e., 691-865 mL/h/kg), and steady state volume of distribution (i.e., 2040-3500 mL/kg) of supinoxin remained unchanged, suggesting dose-independent (i.e., dose-proportional) pharmacokinetics for the dose ranges studied.",Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33799884/),[ml] / [kg],2040-3500,141853,DB00264,Metoprolol
,33799884,absolute oral bioavailability,"After oral administration, supinoxin showed modest absorption with an absolute oral bioavailability of 56.9-57.4%.",Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33799884/),%,56.9-57.4,141854,DB00264,Metoprolol
,33799884,fecal recovery,"The fecal recovery following intravenous and oral administration was 16.5% and 46.8%, respectively, whereas the urinary recoveries in both administration routes were negligible.",Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33799884/),%,16.5,141855,DB00264,Metoprolol
,33799884,fecal recovery,"The fecal recovery following intravenous and oral administration was 16.5% and 46.8%, respectively, whereas the urinary recoveries in both administration routes were negligible.",Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33799884/),%,46.8,141856,DB00264,Metoprolol
,12915955,oral clearance,"Mean values of oral clearance (in l/h/kg) in Groups 1, 2, and 3 were estimated to be 1.2, 1.0, and 0.49, respectively.",Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915955/),[l] / [h·kg],1.2,144392,DB00264,Metoprolol
,12915955,oral clearance,"Mean values of oral clearance (in l/h/kg) in Groups 1, 2, and 3 were estimated to be 1.2, 1.0, and 0.49, respectively.",Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915955/),[l] / [h·kg],1.0,144393,DB00264,Metoprolol
,12915955,oral clearance,"Mean values of oral clearance (in l/h/kg) in Groups 1, 2, and 3 were estimated to be 1.2, 1.0, and 0.49, respectively.",Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915955/),[l] / [h·kg],0.49,144394,DB00264,Metoprolol
,17324642,m/z,The mass transition ion-pair was followed as m/z 326.2-->116.1 for bisoprolol and m/z 268.2-->191.0 for metoprolol.,A high throughput and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of bisoprolol in human plasma using multiplexing technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324642/),,326.2,146028,DB00264,Metoprolol
,17324642,m/z,The mass transition ion-pair was followed as m/z 326.2-->116.1 for bisoprolol and m/z 268.2-->191.0 for metoprolol.,A high throughput and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of bisoprolol in human plasma using multiplexing technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324642/),,116.1,146029,DB00264,Metoprolol
,17324642,m/z,The mass transition ion-pair was followed as m/z 326.2-->116.1 for bisoprolol and m/z 268.2-->191.0 for metoprolol.,A high throughput and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of bisoprolol in human plasma using multiplexing technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324642/),,268.2,146030,DB00264,Metoprolol
,17324642,m/z,The mass transition ion-pair was followed as m/z 326.2-->116.1 for bisoprolol and m/z 268.2-->191.0 for metoprolol.,A high throughput and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of bisoprolol in human plasma using multiplexing technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324642/),,191.0,146031,DB00264,Metoprolol
,17324642,overall recoveries,"The overall recoveries for bisoprolol and metoprolol were 93.89% and 77.65%, respectively.",A high throughput and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of bisoprolol in human plasma using multiplexing technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324642/),%,93.89,146032,DB00264,Metoprolol
,17324642,overall recoveries,"The overall recoveries for bisoprolol and metoprolol were 93.89% and 77.65%, respectively.",A high throughput and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of bisoprolol in human plasma using multiplexing technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324642/),%,77.65,146033,DB00264,Metoprolol
,17324642,Total MS run time,Total MS run time was 0.90 min only.,A high throughput and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of bisoprolol in human plasma using multiplexing technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324642/),min,0.90,146034,DB00264,Metoprolol
,28189955,detection limits,Linear calibration ranges were obtained in the range 0.05-2.0μgmL-1 for FLD and MET and 0.1-2.0μgmL-1 for RAM with detection limits of 0.013-0.031μgmL-1 for all the studied drug combinations.,Ultrasound assisted dispersive liquid-liquid microextraction coupled with high performance liquid chromatography designated for bioavailability studies of felodipine combinations in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28189955/),1/[μgml],0.013-0.031,147977,DB00264,Metoprolol
,22528506,Ratios of absorption rate constants,Ratios of absorption rate constants (synthetic solution method/oral solution) ranged from 1 to 1.3.,A technique to estimate in vivo dissolution profiles without data from a solution. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528506/),,1 to 1.3,148083,DB00264,Metoprolol
,2488104,peak concentrations,"The mean peak concentrations for CR 100 mg, 200 mg, Durules, and the plain tablets were 231, 426, 790, and 1105 nmol/l, respectively.",Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulations of metoprolol [correction of motoprolol] in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2488104/),[nM] / [l],231,152643,DB00264,Metoprolol
,2488104,peak concentrations,"The mean peak concentrations for CR 100 mg, 200 mg, Durules, and the plain tablets were 231, 426, 790, and 1105 nmol/l, respectively.",Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulations of metoprolol [correction of motoprolol] in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2488104/),[nM] / [l],426,152644,DB00264,Metoprolol
,2488104,peak concentrations,"The mean peak concentrations for CR 100 mg, 200 mg, Durules, and the plain tablets were 231, 426, 790, and 1105 nmol/l, respectively.",Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulations of metoprolol [correction of motoprolol] in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2488104/),[nM] / [l],790,152645,DB00264,Metoprolol
,2488104,peak concentrations,"The mean peak concentrations for CR 100 mg, 200 mg, Durules, and the plain tablets were 231, 426, 790, and 1105 nmol/l, respectively.",Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulations of metoprolol [correction of motoprolol] in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2488104/),[nM] / [l],1105,152646,DB00264,Metoprolol
>,24186263,AUC ratio,The static model predicted in vivo interaction with predicted AUC ratio values of >1.1 for all CYP (except CYP3A4).,"Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24186263/),,1.1,154701,DB00264,Metoprolol
,10426558,Ki,"The mefloquine Ki of metoprolol alpha-hydroxylation and O-demethylation were 3.4 and 5.8 microM respectively, whereas those of halofantrine were 0.15 and 0.32 microM respectively.","In vitro effects of racemates, separate enantiomers and major metabolites of mefloquine and halofantrine on metoprolol biotransformation by rat liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426558/),μM,3.4,156476,DB00264,Metoprolol
,10426558,Ki,"The mefloquine Ki of metoprolol alpha-hydroxylation and O-demethylation were 3.4 and 5.8 microM respectively, whereas those of halofantrine were 0.15 and 0.32 microM respectively.","In vitro effects of racemates, separate enantiomers and major metabolites of mefloquine and halofantrine on metoprolol biotransformation by rat liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426558/),μM,5.8,156477,DB00264,Metoprolol
,10426558,Ki,"The mefloquine Ki of metoprolol alpha-hydroxylation and O-demethylation were 3.4 and 5.8 microM respectively, whereas those of halofantrine were 0.15 and 0.32 microM respectively.","In vitro effects of racemates, separate enantiomers and major metabolites of mefloquine and halofantrine on metoprolol biotransformation by rat liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426558/),μM,0.15,156478,DB00264,Metoprolol
,10426558,Ki,"The mefloquine Ki of metoprolol alpha-hydroxylation and O-demethylation were 3.4 and 5.8 microM respectively, whereas those of halofantrine were 0.15 and 0.32 microM respectively.","In vitro effects of racemates, separate enantiomers and major metabolites of mefloquine and halofantrine on metoprolol biotransformation by rat liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426558/),μM,0.32,156479,DB00264,Metoprolol
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],116.95,156601,DB00264,Metoprolol
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],201.23,156602,DB00264,Metoprolol
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],8.01,156603,DB00264,Metoprolol
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],18.87,156604,DB00264,Metoprolol
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],485.16,156605,DB00264,Metoprolol
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],843.88,156606,DB00264,Metoprolol
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],2.67,156607,DB00264,Metoprolol
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],4.11,156608,DB00264,Metoprolol
,31852530,Css,"The final regression models included hormonal status as the only predictor for Css of tamoxifen [β-coef ± SE, p-value (75.03 ± 17.71, p = 0.0001)] and 4-hydroxytamoxifen (1.7822 ± 0.4385, p = 0.0002), while endoxifen Css included hormonal status (8.578 ± 3.402, p = 0.02) and race (11.945 ± 2.836, p = 0.007).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),,8.578,156609,DB00264,Metoprolol
,31852530,Css,"The final regression models included hormonal status as the only predictor for Css of tamoxifen [β-coef ± SE, p-value (75.03 ± 17.71, p = 0.0001)] and 4-hydroxytamoxifen (1.7822 ± 0.4385, p = 0.0002), while endoxifen Css included hormonal status (8.578 ± 3.402, p = 0.02) and race (11.945 ± 2.836, p = 0.007).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),,11.945,156610,DB00264,Metoprolol
,7568317,recovery rates,High recovery rates (80-95%) were achieved by means of a liquid-liquid-extraction at pH 11 with dichloromethane as solvent.,Quantitation of R- and S-propafenone and of the main metabolite in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7568317/),%,80-95,157196,DB00264,Metoprolol
,7568317,k',The obtained capacity factors are k' = 2.36 for R-propafenone and k' = 3.82 for S-propafenone.,Quantitation of R- and S-propafenone and of the main metabolite in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7568317/),,2.36,157197,DB00264,Metoprolol
,7568317,k',The obtained capacity factors are k' = 2.36 for R-propafenone and k' = 3.82 for S-propafenone.,Quantitation of R- and S-propafenone and of the main metabolite in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7568317/),,3.82,157198,DB00264,Metoprolol
,3935852,elimination half-life,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),h,1.35,158315,DB00264,Metoprolol
,3935852,elimination half-life,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),h,1.10,158316,DB00264,Metoprolol
,3935852,elimination half-life,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),h,1.09,158317,DB00264,Metoprolol
,3935852,total area under the curve,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[ng] / [h·ml],42,158318,DB00264,Metoprolol
,3935852,total area under the curve,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[ng] / [h·ml],38,158319,DB00264,Metoprolol
,3935852,oral clearance,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[l] / [min],6.6,158320,DB00264,Metoprolol
,3935852,oral clearance,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[l] / [min],7.2,158321,DB00264,Metoprolol
,3935852,oral clearance,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[l] / [min],6.4,158322,DB00264,Metoprolol
,27442605,V,"Final parameter estimates were V, 63.4 L, maximum rate [Vm], 9.57 mg h-1, Michaelis constant [Km], 1.97 mg L-1.",Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),l,63.4,159028,DB00264,Metoprolol
,27442605,maximum rate [Vm],"Final parameter estimates were V, 63.4 L, maximum rate [Vm], 9.57 mg h-1, Michaelis constant [Km], 1.97 mg L-1.",Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),[mg] / [h],9.57,159029,DB00264,Metoprolol
,27442605,Michaelis constant [Km],"Final parameter estimates were V, 63.4 L, maximum rate [Vm], 9.57 mg h-1, Michaelis constant [Km], 1.97 mg L-1.",Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),[mg] / [l],1.97,159030,DB00264,Metoprolol
,27442605,elimination half-life,Predicted elimination half-life decreased from 20 h over time until there was first order elimination with a half-life 9 h.,Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),h,20,159031,DB00264,Metoprolol
,27442605,half-life,Predicted elimination half-life decreased from 20 h over time until there was first order elimination with a half-life 9 h.,Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),h,9,159032,DB00264,Metoprolol
,12891223,area under the plasma concentration-time curve,"Celecoxib significantly increased the area under the plasma concentration-time curve of metoprolol from 271 to 414 micro g. h/L (64% +/- 57%, P <.001) and by more than 200% in 1 volunteer.",Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891223/),[h·μg] / [l],271 to 414,161598,DB00264,Metoprolol
,12891223,area under the plasma concentration-time curve from 0 to 24 hours,"After administration of celecoxib, the area under the plasma concentration-time curve from 0 to 24 hours of alpha-hydroxymetoprolol decreased significantly from 474 to 387 micro g. h/L (P <.01).",Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891223/),[h·μg] / [l],474,161599,DB00264,Metoprolol
,12891223,area under the plasma concentration-time curve from 0 to 24 hours,"After administration of celecoxib, the area under the plasma concentration-time curve from 0 to 24 hours of alpha-hydroxymetoprolol decreased significantly from 474 to 387 micro g. h/L (P <.01).",Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891223/),[h·μg] / [l],38,161600,DB00264,Metoprolol
,16995327,area under the plasma concentration-time curve,No effect of valdecoxib (20 mg/d) or rofecoxib (25 mg/d) were detected on the area under the plasma concentration-time curve of metoprolol (323 +/- 333 to 324 +/- 296 or 309 +/- 256 microg x h/l) or at a higher dose.,Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995327/),[h·μg] / [l],323,164280,DB00264,Metoprolol
,16995327,area under the plasma concentration-time curve,No effect of valdecoxib (20 mg/d) or rofecoxib (25 mg/d) were detected on the area under the plasma concentration-time curve of metoprolol (323 +/- 333 to 324 +/- 296 or 309 +/- 256 microg x h/l) or at a higher dose.,Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995327/),[h·μg] / [l],324,164281,DB00264,Metoprolol
,16995327,area under the plasma concentration-time curve,No effect of valdecoxib (20 mg/d) or rofecoxib (25 mg/d) were detected on the area under the plasma concentration-time curve of metoprolol (323 +/- 333 to 324 +/- 296 or 309 +/- 256 microg x h/l) or at a higher dose.,Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995327/),[h·μg] / [l],309,164282,DB00264,Metoprolol
,15470329,total metoprolol clearance,"Median total metoprolol clearance values were 31, 168, and 367 L/h and median maximum plasma concentrations were 260, 118, and 67 microg/L in PMs, EMs, and UMs, respectively ( P < .0001).",Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470329/),[l] / [h],31,164958,DB00264,Metoprolol
,15470329,total metoprolol clearance,"Median total metoprolol clearance values were 31, 168, and 367 L/h and median maximum plasma concentrations were 260, 118, and 67 microg/L in PMs, EMs, and UMs, respectively ( P < .0001).",Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470329/),[l] / [h],168,164959,DB00264,Metoprolol
,15470329,total metoprolol clearance,"Median total metoprolol clearance values were 31, 168, and 367 L/h and median maximum plasma concentrations were 260, 118, and 67 microg/L in PMs, EMs, and UMs, respectively ( P < .0001).",Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470329/),[l] / [h],367,164960,DB00264,Metoprolol
,15470329,maximum plasma concentrations,"Median total metoprolol clearance values were 31, 168, and 367 L/h and median maximum plasma concentrations were 260, 118, and 67 microg/L in PMs, EMs, and UMs, respectively ( P < .0001).",Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470329/),[μg] / [l],260,164961,DB00264,Metoprolol
,15470329,maximum plasma concentrations,"Median total metoprolol clearance values were 31, 168, and 367 L/h and median maximum plasma concentrations were 260, 118, and 67 microg/L in PMs, EMs, and UMs, respectively ( P < .0001).",Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470329/),[μg] / [l],118,164962,DB00264,Metoprolol
,15470329,maximum plasma concentrations,"Median total metoprolol clearance values were 31, 168, and 367 L/h and median maximum plasma concentrations were 260, 118, and 67 microg/L in PMs, EMs, and UMs, respectively ( P < .0001).",Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470329/),[μg] / [l],67,164963,DB00264,Metoprolol
,6125199,elimination half-life,A slight but significant increase in the elimination half-life from 6.5 +/- 0.6 to 7.9 +/- 0.6 (P less than 0.05) was noted for atenolol after pretreatment with cimetidine.,The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125199/),,6.5,167150,DB00264,Metoprolol
,6125199,elimination half-life,A slight but significant increase in the elimination half-life from 6.5 +/- 0.6 to 7.9 +/- 0.6 (P less than 0.05) was noted for atenolol after pretreatment with cimetidine.,The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125199/),,7.9,167151,DB00264,Metoprolol
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],4.6,168775,DB00264,Metoprolol
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],3.7,168776,DB00264,Metoprolol
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],3.3,168777,DB00264,Metoprolol
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],2.7,168778,DB00264,Metoprolol
,25364857,clearance (CL),The mean clearance (CL) values of midazolam in aged monkeys (9.5 mL/min/kg) were significantly lower than those in young monkeys (13 mL/min/kg).,"Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[ml] / [kg·min],9.5,168779,DB00264,Metoprolol
,25364857,clearance (CL),The mean clearance (CL) values of midazolam in aged monkeys (9.5 mL/min/kg) were significantly lower than those in young monkeys (13 mL/min/kg).,"Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[ml] / [kg·min],13,168780,DB00264,Metoprolol
,24724915,Tmax,"The Tmax obtained from the two buccal conscious groups (55 ± 5 and 35 ± 5 min) were significantly different to the buccal anaesthetised groups (120 ± 0 and 165 ± 15 min) for buccal tablet pH 6.2 and pH 8.9, respectively.",Conscious and anaesthetised Göttingen mini-pigs as an in-vivo model for buccal absorption - pH-dependent absorption of metoprolol from bioadhesive tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24724915/),min,55,171854,DB00264,Metoprolol
,24724915,Tmax,"The Tmax obtained from the two buccal conscious groups (55 ± 5 and 35 ± 5 min) were significantly different to the buccal anaesthetised groups (120 ± 0 and 165 ± 15 min) for buccal tablet pH 6.2 and pH 8.9, respectively.",Conscious and anaesthetised Göttingen mini-pigs as an in-vivo model for buccal absorption - pH-dependent absorption of metoprolol from bioadhesive tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24724915/),min,35,171855,DB00264,Metoprolol
,24724915,Tmax,"The Tmax obtained from the two buccal conscious groups (55 ± 5 and 35 ± 5 min) were significantly different to the buccal anaesthetised groups (120 ± 0 and 165 ± 15 min) for buccal tablet pH 6.2 and pH 8.9, respectively.",Conscious and anaesthetised Göttingen mini-pigs as an in-vivo model for buccal absorption - pH-dependent absorption of metoprolol from bioadhesive tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24724915/),min,120,171856,DB00264,Metoprolol
,24724915,Tmax,"The Tmax obtained from the two buccal conscious groups (55 ± 5 and 35 ± 5 min) were significantly different to the buccal anaesthetised groups (120 ± 0 and 165 ± 15 min) for buccal tablet pH 6.2 and pH 8.9, respectively.",Conscious and anaesthetised Göttingen mini-pigs as an in-vivo model for buccal absorption - pH-dependent absorption of metoprolol from bioadhesive tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24724915/),min,165,171857,DB00264,Metoprolol
,24724915,absolute bioavailability,"Also, the absolute bioavailability from the anaesthetised buccal tablet pH 8.9 (20.7 ± 4.0%) had a significant increase compared to all other buccal tablet groups.",Conscious and anaesthetised Göttingen mini-pigs as an in-vivo model for buccal absorption - pH-dependent absorption of metoprolol from bioadhesive tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24724915/),%,20.7,171858,DB00264,Metoprolol
,26385166,relative bioavailability,"The relative bioavailability for the linear, extended release profiles was about 85% which is similar to other extended release administrations of metoprolol.",Validation of the IntelliCap® system as a tool to evaluate extended release profiles in human GI tract using metoprolol as model drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26385166/),%,85,174670,DB00264,Metoprolol
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],40,175115,DB00264,Metoprolol
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],37,175116,DB00264,Metoprolol
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],22,175117,DB00264,Metoprolol
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],55,175118,DB00264,Metoprolol
,18043474,serum concentrations,"At 60, 90, and 120 mg/day, the mean +/- SD serum concentrations were 33+/-22.0, 43+/-22.2, and 48+/-17.0 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],33,175119,DB00264,Metoprolol
,18043474,serum concentrations,"At 60, 90, and 120 mg/day, the mean +/- SD serum concentrations were 33+/-22.0, 43+/-22.2, and 48+/-17.0 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],43,175120,DB00264,Metoprolol
,18043474,serum concentrations,"At 60, 90, and 120 mg/day, the mean +/- SD serum concentrations were 33+/-22.0, 43+/-22.2, and 48+/-17.0 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],48,175121,DB00264,Metoprolol
,21414851,detection limit (S/N=3),"The linear ranges of the standard solution for atenolol and esmolol were 2.5-125 μmol/L with a detection limit (S/N=3) of 0.5 μmol/L, and for metoprolol was 0.5-25 μmol/L with a detection limit of 0.1 μmol/L.",Determination of β-blockers in pharmaceutical and human urine by capillary electrophoresis with electrochemiluminescence detection and studies on the pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21414851/),[μM] / [l],0.5,177583,DB00264,Metoprolol
,21414851,detection limit,"The linear ranges of the standard solution for atenolol and esmolol were 2.5-125 μmol/L with a detection limit (S/N=3) of 0.5 μmol/L, and for metoprolol was 0.5-25 μmol/L with a detection limit of 0.1 μmol/L.",Determination of β-blockers in pharmaceutical and human urine by capillary electrophoresis with electrochemiluminescence detection and studies on the pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21414851/),[μM] / [l],0.1,177584,DB00264,Metoprolol
,21414851,recoveries,"The developed method was applied to the determination of metoprolol content in commercial pharmaceutical, and the analytical results are in good agreement with the nominal value with recoveries in the range of 98.7-105%.",Determination of β-blockers in pharmaceutical and human urine by capillary electrophoresis with electrochemiluminescence detection and studies on the pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21414851/),%,98.7-105,177585,DB00264,Metoprolol
,23355638,steady-state plasma concentration (Css) ratio,The predicted mean PAR steady-state plasma concentration (Css) ratio (PP:T3) was 7.1 versus the observed value 3.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,7.1,179595,DB00264,Metoprolol
,23355638,steady-state plasma concentration (Css) ratio,The predicted mean PAR steady-state plasma concentration (Css) ratio (PP:T3) was 7.1 versus the observed value 3.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,3.7,179596,DB00264,Metoprolol
,23355638,AUC ratio,Predicted mean CLO AUC ratio (PP:T3) was 2.2 versus the observed value 1.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,2.2,179597,DB00264,Metoprolol
,23355638,AUC ratio,Predicted mean CLO AUC ratio (PP:T3) was 2.2 versus the observed value 1.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,1.7,179598,DB00264,Metoprolol
,28209351,AUC,"Regarding to the nebivolol glucuronide isomers, higher plasma concentrations of the d-isomer were observed compared to the l-isomer (d/l AUC=5.4), explaining at least in part the plasma accumulation of unchanged l-nebivolol (l/d AUC=1.8).",An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),,5.4,179615,DB00264,Metoprolol
,28209351,AUC,"Regarding to the nebivolol glucuronide isomers, higher plasma concentrations of the d-isomer were observed compared to the l-isomer (d/l AUC=5.4), explaining at least in part the plasma accumulation of unchanged l-nebivolol (l/d AUC=1.8).",An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),,1.8,179616,DB00264,Metoprolol
,28209351,ratios,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),,6.5,179617,DB00264,Metoprolol
,28209351,AUC,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),[ngh] / [ml],65.3,179618,DB00264,Metoprolol
,28209351,AUC,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),[ngh] / [ml],10.1,179619,DB00264,Metoprolol
,28209351,AUC,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),[ngh] / [ml],62.1,179620,DB00264,Metoprolol
,28209351,AUC,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),[ngh] / [ml],335.2,179621,DB00264,Metoprolol
,28209351,AUC,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),[ngh] / [ml],5.4,179622,DB00264,Metoprolol
,18475202,Emax,"Metoprolol induced a greater hypotensive effect in fructose-fed animals (Emax: -24 +/- 1 mm Hg, n = 6, P < 0.05 vs. control) than in control rats (Emax: -14 +/- 1 mm Hg, n = 6).",In vitro and in vivo pharmacodynamic properties of metoprolol in fructose-fed hypertensive rats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475202/),hg·mm,-24,180324,DB00264,Metoprolol
,18475202,Emax,"Metoprolol induced a greater hypotensive effect in fructose-fed animals (Emax: -24 +/- 1 mm Hg, n = 6, P < 0.05 vs. control) than in control rats (Emax: -14 +/- 1 mm Hg, n = 6).",In vitro and in vivo pharmacodynamic properties of metoprolol in fructose-fed hypertensive rats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475202/),hg·mm,-14,180325,DB00264,Metoprolol
,18475202,IC50,"Bradycardic response was similar in both groups; metoprolol chronotropic potency was greater in fructose-fed rats (IC50: 123 +/- 15 ng/mL, P < 0.05 vs. control) compared to control animals (IC50: 216 +/- 36 ng/mL) after administration of 3 mg/kg.",In vitro and in vivo pharmacodynamic properties of metoprolol in fructose-fed hypertensive rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475202/),[ng] / [ml],123,180326,DB00264,Metoprolol
,18475202,IC50,"Bradycardic response was similar in both groups; metoprolol chronotropic potency was greater in fructose-fed rats (IC50: 123 +/- 15 ng/mL, P < 0.05 vs. control) compared to control animals (IC50: 216 +/- 36 ng/mL) after administration of 3 mg/kg.",In vitro and in vivo pharmacodynamic properties of metoprolol in fructose-fed hypertensive rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475202/),,216,180327,DB00264,Metoprolol
,29193123,AUC(0-24) ratios,"Predicted and observed metoprolol geometric least-squares mean AUC(0-24) ratios in UM vs EM were also similar (0.46 and 0.55, respectively), suggesting that system components related to CYP2D6 in the PBPK model were properly established.",Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29193123/),,0.46,180852,DB00264,Metoprolol
,29193123,AUC(0-24) ratios,"Predicted and observed metoprolol geometric least-squares mean AUC(0-24) ratios in UM vs EM were also similar (0.46 and 0.55, respectively), suggesting that system components related to CYP2D6 in the PBPK model were properly established.",Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29193123/),,0.55,180853,DB00264,Metoprolol
,6160322,"t1/2, beta","The mean t1/2, beta was 3.6 hr for both drugs, but due to a larger volume of distribution, the total body clearance was significantly higher for metoprolol (1.20 liters/min) than for propranolol (0.81 liters/min).",Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160322/),h,3.6,181049,DB00264,Metoprolol
,6160322,total body clearance,"The mean t1/2, beta was 3.6 hr for both drugs, but due to a larger volume of distribution, the total body clearance was significantly higher for metoprolol (1.20 liters/min) than for propranolol (0.81 liters/min).",Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160322/),[l] / [min],1.20,181050,DB00264,Metoprolol
,6160322,total body clearance,"The mean t1/2, beta was 3.6 hr for both drugs, but due to a larger volume of distribution, the total body clearance was significantly higher for metoprolol (1.20 liters/min) than for propranolol (0.81 liters/min).",Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160322/),[l] / [min],0.81,181051,DB00264,Metoprolol
,7333059,fraction of the drug available,The mean fraction of the drug available systematically was 84 +/- 10% in patients and 50 +/- 11% in a control group of 6 healthy subjects (p less than 0.05).,Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333059/),%,84,181425,DB00264,Metoprolol
,7333059,fraction of the drug available,The mean fraction of the drug available systematically was 84 +/- 10% in patients and 50 +/- 11% in a control group of 6 healthy subjects (p less than 0.05).,Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333059/),%,50,181426,DB00264,Metoprolol
,7333059,total body clearance,The total body clearance of metoprolol in the cirrhotics was 0.61 +/- 0.13L/min and in the controls 0.80 +/- 0.11L/min.,Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333059/),[l] / [min],0.61,181427,DB00264,Metoprolol
,7333059,total body clearance,The total body clearance of metoprolol in the cirrhotics was 0.61 +/- 0.13L/min and in the controls 0.80 +/- 0.11L/min.,Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333059/),[l] / [min],0.80,181428,DB00264,Metoprolol
,7333059,elimination half-lives,"These values correspond to elimination half-lives of 7.2 +/- 1.2 and 4.2 +/- 1.1 hours, respectively.",Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333059/),h,7.2,181429,DB00264,Metoprolol
,7333059,elimination half-lives,"These values correspond to elimination half-lives of 7.2 +/- 1.2 and 4.2 +/- 1.1 hours, respectively.",Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333059/),h,4.2,181430,DB00264,Metoprolol
,25291152,tmax,Well-controlled GDM prolonged tmax for both enantiomers of metoprolol (1.5 vs.,Influence of gestational diabetes on the stereoselective pharmacokinetics and placental distribution of metoprolol and its metabolites in parturients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25291152/),,1.5,184847,DB00264,Metoprolol
,1968913,maximal beta 1-blocking effect (Emax),The maximal beta 1-blocking effect (Emax) was 28% (95% confidence interval: 25-31%) and the plasma concentration for obtaining 50% of Emax (C50) was 105 nmol/L (95% confidence interval: 74-135 nmol/L).,The relationship between metoprolol plasma concentration and beta 1-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1968913/),%,28,185612,DB00264,Metoprolol
,1968913,Emax (C50),The maximal beta 1-blocking effect (Emax) was 28% (95% confidence interval: 25-31%) and the plasma concentration for obtaining 50% of Emax (C50) was 105 nmol/L (95% confidence interval: 74-135 nmol/L).,The relationship between metoprolol plasma concentration and beta 1-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1968913/),[nM] / [l],105,185613,DB00264,Metoprolol
,31862675,recovery (%),"Mean recovery (%) values in aqueous humor and plasma were 72.4% and 73.0% for nebivolol and 56.7% and 54.4% for labetalol, respectively.",Development and validation of a bio-analytical method for simultaneous quantification of nebivolol and labetalol in aqueous humor and plasma using LC-MS/MS and its application to ocular pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862675/),%,72.4,187766,DB00264,Metoprolol
,31862675,recovery (%),"Mean recovery (%) values in aqueous humor and plasma were 72.4% and 73.0% for nebivolol and 56.7% and 54.4% for labetalol, respectively.",Development and validation of a bio-analytical method for simultaneous quantification of nebivolol and labetalol in aqueous humor and plasma using LC-MS/MS and its application to ocular pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862675/),%,73.0,187767,DB00264,Metoprolol
,31862675,recovery (%),"Mean recovery (%) values in aqueous humor and plasma were 72.4% and 73.0% for nebivolol and 56.7% and 54.4% for labetalol, respectively.",Development and validation of a bio-analytical method for simultaneous quantification of nebivolol and labetalol in aqueous humor and plasma using LC-MS/MS and its application to ocular pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862675/),%,56.7,187768,DB00264,Metoprolol
,31862675,recovery (%),"Mean recovery (%) values in aqueous humor and plasma were 72.4% and 73.0% for nebivolol and 56.7% and 54.4% for labetalol, respectively.",Development and validation of a bio-analytical method for simultaneous quantification of nebivolol and labetalol in aqueous humor and plasma using LC-MS/MS and its application to ocular pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862675/),%,54.4,187769,DB00264,Metoprolol
,17220566,C/D ratio,"The dose of metoprolol and patient age were significantly higher in the MET group when compared with the MET+AMD group (1.00+/-0.480 versus 0.767+/-0.418 mg/kg/day, p<0.050; 68.6+/-10.6 versus 57.6+/-14.1 years, p<0.001, respectively), but the C/D ratio was significantly lower in the MET group than in the MET+AMD group (90.8+/-64.0 versus 136+/-97.8, p<0.01).",Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220566/),,90.8,189038,DB00264,Metoprolol
,17220566,C/D ratio,"The dose of metoprolol and patient age were significantly higher in the MET group when compared with the MET+AMD group (1.00+/-0.480 versus 0.767+/-0.418 mg/kg/day, p<0.050; 68.6+/-10.6 versus 57.6+/-14.1 years, p<0.001, respectively), but the C/D ratio was significantly lower in the MET group than in the MET+AMD group (90.8+/-64.0 versus 136+/-97.8, p<0.01).",Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220566/),,136,189039,DB00264,Metoprolol
,10080652,recovery,Plasma samples were extracted with ethyl acetate in a one-step liquid-liquid extraction (recovery 88.5+/-2.1%).,High-performance liquid chromatographic method for determination of tramadol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080652/),%,88.5,191919,DB00264,Metoprolol
,10080652,A,Accuracy of the assay in the concentration range examined was from 1.3 to 11.9% for the intra-day run and from 1.4 to 8.1% for the inter-day run.,High-performance liquid chromatographic method for determination of tramadol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080652/),%,1.3 to 11.9,191920,DB00264,Metoprolol
,10080652,limit of detection,A limit of detection was 9 ng/ml at a signal-to-noise ratio of 3.,High-performance liquid chromatographic method for determination of tramadol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080652/),[ng] / [ml],9,191921,DB00264,Metoprolol
,10080652,signal-to-noise ratio,A limit of detection was 9 ng/ml at a signal-to-noise ratio of 3.,High-performance liquid chromatographic method for determination of tramadol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080652/),,3,191922,DB00264,Metoprolol
,14567646,Cmax,Cmax (185.1 +/- 56.8 ng/ml) was reached at hour 3.,Iontophoretic in vivo transdermal delivery of beta-blockers in hairless rats and reduced skin irritation by liposomal formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14567646/),[ng] / [ml],185.1,192387,DB00264,Metoprolol
,32311673,AUC0-∞,"Enantiomeric ratio in plasma (AUC0-∞(R)-(+)/(S)-(-)) was close to 1.5, nevertheless in urine was closed to unity.",Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32311673/),,1.5,192497,DB00264,Metoprolol
,32311673,transplacental transfer,The transplacental transfer was approximately 18% for both fexofenadine enantiomers.,Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32311673/),%,18,192498,DB00264,Metoprolol
,32725383,Vss ratio,"Changes in exposure (area under the curve) up to 5.1-fold were observed; however, ratios of Vss changes have a range of 0.70-1.26, with one outlier displaying a Vss ratio of 0.57.",Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32725383/),,0.57,192758,DB00264,Metoprolol
,3792423,minimum plasma concentration during steady state,The median minimum plasma concentration during steady state averaged around 200 nmol/l and was comparable to the mean trough levels 24 and 48 h after the start of therapy.,Metoprolol in acute myocardial infarction. A pharmacokinetic and pharmacodynamic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792423/),[nM] / [l],200,193434,DB00264,Metoprolol
,3443140,steady-state volume of distribution,The only significant difference between smokers (S) and nonsmokers (NS) was that S had a larger steady-state volume of distribution (3.3 vs 2.5 l/kg).,Influence of smoking and gender on the disposition kinetics of metoprolol. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443140/),[l] / [kg],3.3,196823,DB00264,Metoprolol
,3443140,steady-state volume of distribution,The only significant difference between smokers (S) and nonsmokers (NS) was that S had a larger steady-state volume of distribution (3.3 vs 2.5 l/kg).,Influence of smoking and gender on the disposition kinetics of metoprolol. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443140/),[l] / [kg],2.5,196824,DB00264,Metoprolol
,3443140,Systemic bioavailability,Systemic bioavailability varied markedly between subjects (range: 15 to 92%).,Influence of smoking and gender on the disposition kinetics of metoprolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443140/),%,15 to 92,196825,DB00264,Metoprolol
,14727847,Cmax,"The mean Cmax and AUC(inf) for the small batch of propranolol were 79.0 microg/L and 536 microg/L/hr, and for the large batch they were 83.5 microg/L and 575 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [l],79.0,196843,DB00264,Metoprolol
,14727847,Cmax,"The mean Cmax and AUC(inf) for the small batch of propranolol were 79.0 microg/L and 536 microg/L/hr, and for the large batch they were 83.5 microg/L and 575 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [l],83.5,196844,DB00264,Metoprolol
,14727847,AUC(inf),"The mean Cmax and AUC(inf) for the small batch of propranolol were 79.0 microg/L and 536 microg/L/hr, and for the large batch they were 83.5 microg/L and 575 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [h·l],536,196845,DB00264,Metoprolol
,14727847,AUC(inf),"The mean Cmax and AUC(inf) for the small batch of propranolol were 79.0 microg/L and 536 microg/L/hr, and for the large batch they were 83.5 microg/L and 575 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [h·l],575,196846,DB00264,Metoprolol
,14727847,Cmax,"Cmax and AUC(inf) for the small batch of metoprolol were found to be 95.5 microg/L and 507 microg/L/hr and for the large batch, 95.1 microg/L and 495 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [l],95.5,196847,DB00264,Metoprolol
,14727847,Cmax,"Cmax and AUC(inf) for the small batch of metoprolol were found to be 95.5 microg/L and 507 microg/L/hr and for the large batch, 95.1 microg/L and 495 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [l],95.1,196848,DB00264,Metoprolol
,14727847,AUC(inf),"Cmax and AUC(inf) for the small batch of metoprolol were found to be 95.5 microg/L and 507 microg/L/hr and for the large batch, 95.1 microg/L and 495 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [h·l],507,196849,DB00264,Metoprolol
,14727847,AUC(inf),"Cmax and AUC(inf) for the small batch of metoprolol were found to be 95.5 microg/L and 507 microg/L/hr and for the large batch, 95.1 microg/L and 495 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [h·l],495,196850,DB00264,Metoprolol
,8223839,Cmax,"The controlled-release formulation gave less variable plasma metoprolol concentrations, Cmax 138 nmol.l-1 and Cmin 74 nmol.l-1, whereas for the conventional formulation the mean Cmax of metoprolol was 629 nmol.l-1 and the Cmin 20 nmol.l-1.",The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223839/),[nM] / [l],138,196853,DB00264,Metoprolol
,8223839,Cmin,"The controlled-release formulation gave less variable plasma metoprolol concentrations, Cmax 138 nmol.l-1 and Cmin 74 nmol.l-1, whereas for the conventional formulation the mean Cmax of metoprolol was 629 nmol.l-1 and the Cmin 20 nmol.l-1.",The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223839/),[nM] / [l],74,196854,DB00264,Metoprolol
,8223839,Cmax,"The controlled-release formulation gave less variable plasma metoprolol concentrations, Cmax 138 nmol.l-1 and Cmin 74 nmol.l-1, whereas for the conventional formulation the mean Cmax of metoprolol was 629 nmol.l-1 and the Cmin 20 nmol.l-1.",The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223839/),[nM] / [l],629,196855,DB00264,Metoprolol
,8223839,Cmin,"The controlled-release formulation gave less variable plasma metoprolol concentrations, Cmax 138 nmol.l-1 and Cmin 74 nmol.l-1, whereas for the conventional formulation the mean Cmax of metoprolol was 629 nmol.l-1 and the Cmin 20 nmol.l-1.",The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223839/),[nM] / [l],20,196856,DB00264,Metoprolol
,8223839,relative systemic availability,"Despite lower relative systemic availability (68%) for metoprolol from the controlled-release formulation and a smaller AUC, metoprolol from the controlled-release formulation produced a greater total effect, calculated as the area under the curve of the effect on exercise heart rate vs. time (303 vs. 259%.h; P < 0.05).",The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223839/),%,68,196857,DB00264,Metoprolol
,2284974,detection limit,The detection limit was 1 ng/ml and the linear range was 10-1500 ng/ml (r = 0.9993).,[Determination of metoprolol in plasma by gas chromatography and electron-capture detection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2284974/),[ng] / [ml],1,197123,DB00264,Metoprolol
,2284974,recovery,Average recovery from spiked plasma was 97.30%.,[Determination of metoprolol in plasma by gas chromatography and electron-capture detection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2284974/),%,97.30,197124,DB00264,Metoprolol
,18834373,AUC(0-->infinity)s,"The AUC(0-->infinity)s of metoprolol were 443.7 +/- 168.1, 995.6 +/- 321.4 and 2545.3 +/- 632.0 ng.h/mL, and the AUC(0-->infinity)s of alpha-hydroxymetoprolol were 1232.0 +/- 311.2, 1344.0 +/- 288.1 and 877.4 +/- 103.4 ng.h/mL for groups CYP2D6*1/*1, *1/*10 and *10/*10, respectively.",Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18834373/),[h·ng] / [ml],443.7,197781,DB00264,Metoprolol
,18834373,AUC(0-->infinity)s,"The AUC(0-->infinity)s of metoprolol were 443.7 +/- 168.1, 995.6 +/- 321.4 and 2545.3 +/- 632.0 ng.h/mL, and the AUC(0-->infinity)s of alpha-hydroxymetoprolol were 1232.0 +/- 311.2, 1344.0 +/- 288.1 and 877.4 +/- 103.4 ng.h/mL for groups CYP2D6*1/*1, *1/*10 and *10/*10, respectively.",Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18834373/),[h·ng] / [ml],995.6,197782,DB00264,Metoprolol
,18834373,AUC(0-->infinity)s,"The AUC(0-->infinity)s of metoprolol were 443.7 +/- 168.1, 995.6 +/- 321.4 and 2545.3 +/- 632.0 ng.h/mL, and the AUC(0-->infinity)s of alpha-hydroxymetoprolol were 1232.0 +/- 311.2, 1344.0 +/- 288.1 and 877.4 +/- 103.4 ng.h/mL for groups CYP2D6*1/*1, *1/*10 and *10/*10, respectively.",Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18834373/),[h·ng] / [ml],2545.3,197783,DB00264,Metoprolol
,18834373,AUC(0-->infinity)s,"The AUC(0-->infinity)s of metoprolol were 443.7 +/- 168.1, 995.6 +/- 321.4 and 2545.3 +/- 632.0 ng.h/mL, and the AUC(0-->infinity)s of alpha-hydroxymetoprolol were 1232.0 +/- 311.2, 1344.0 +/- 288.1 and 877.4 +/- 103.4 ng.h/mL for groups CYP2D6*1/*1, *1/*10 and *10/*10, respectively.",Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18834373/),[h·ng] / [ml],1232.0,197784,DB00264,Metoprolol
,18834373,AUC(0-->infinity)s,"The AUC(0-->infinity)s of metoprolol were 443.7 +/- 168.1, 995.6 +/- 321.4 and 2545.3 +/- 632.0 ng.h/mL, and the AUC(0-->infinity)s of alpha-hydroxymetoprolol were 1232.0 +/- 311.2, 1344.0 +/- 288.1 and 877.4 +/- 103.4 ng.h/mL for groups CYP2D6*1/*1, *1/*10 and *10/*10, respectively.",Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18834373/),[h·ng] / [ml],1344.0,197785,DB00264,Metoprolol
,18834373,AUC(0-->infinity)s,"The AUC(0-->infinity)s of metoprolol were 443.7 +/- 168.1, 995.6 +/- 321.4 and 2545.3 +/- 632.0 ng.h/mL, and the AUC(0-->infinity)s of alpha-hydroxymetoprolol were 1232.0 +/- 311.2, 1344.0 +/- 288.1 and 877.4 +/- 103.4 ng.h/mL for groups CYP2D6*1/*1, *1/*10 and *10/*10, respectively.",Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18834373/),[h·ng] / [ml],877.4,197786,DB00264,Metoprolol
,18834373,T(1/2),"The corresponding T(1/2) values of metoprolol were 2.7 +/- 0.5, 3.2 +/- 1.3 and 5.0 +/- 1.1 h, while those of alpha-hydroxymetoprolol were 5.4+/-1.5, 6.0 +/- 1.4 and 10.5 +/- 4.2 h, respectively.",Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18834373/),h,2.7,197787,DB00264,Metoprolol
,18834373,T(1/2),"The corresponding T(1/2) values of metoprolol were 2.7 +/- 0.5, 3.2 +/- 1.3 and 5.0 +/- 1.1 h, while those of alpha-hydroxymetoprolol were 5.4+/-1.5, 6.0 +/- 1.4 and 10.5 +/- 4.2 h, respectively.",Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18834373/),h,3.2,197788,DB00264,Metoprolol
,18834373,T(1/2),"The corresponding T(1/2) values of metoprolol were 2.7 +/- 0.5, 3.2 +/- 1.3 and 5.0 +/- 1.1 h, while those of alpha-hydroxymetoprolol were 5.4+/-1.5, 6.0 +/- 1.4 and 10.5 +/- 4.2 h, respectively.",Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18834373/),h,5.0,197789,DB00264,Metoprolol
,18834373,T(1/2),"The corresponding T(1/2) values of metoprolol were 2.7 +/- 0.5, 3.2 +/- 1.3 and 5.0 +/- 1.1 h, while those of alpha-hydroxymetoprolol were 5.4+/-1.5, 6.0 +/- 1.4 and 10.5 +/- 4.2 h, respectively.",Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18834373/),h,5.4,197790,DB00264,Metoprolol
,18834373,T(1/2),"The corresponding T(1/2) values of metoprolol were 2.7 +/- 0.5, 3.2 +/- 1.3 and 5.0 +/- 1.1 h, while those of alpha-hydroxymetoprolol were 5.4+/-1.5, 6.0 +/- 1.4 and 10.5 +/- 4.2 h, respectively.",Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18834373/),h,6.0,197791,DB00264,Metoprolol
,18834373,T(1/2),"The corresponding T(1/2) values of metoprolol were 2.7 +/- 0.5, 3.2 +/- 1.3 and 5.0 +/- 1.1 h, while those of alpha-hydroxymetoprolol were 5.4+/-1.5, 6.0 +/- 1.4 and 10.5 +/- 4.2 h, respectively.",Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18834373/),h,10.5,197792,DB00264,Metoprolol
,27006091,peak concentrations of unbound plasma concentration,"The peak concentrations of unbound plasma concentration of MET, α-hydroxy metoprolol (HM), O-desmethyl metoprolol (ODM) and N-desisopropyl metoprolol (DIM) were 90.37 ± 2.69, 33.32 ± 1.92, 16.93 ± 1.70 and 7.96 ± 0.94 ng/mL, respectively.",An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006091/),[ng] / [ml],90.37,202305,DB00264,Metoprolol
,27006091,peak concentrations of unbound plasma concentration,"The peak concentrations of unbound plasma concentration of MET, α-hydroxy metoprolol (HM), O-desmethyl metoprolol (ODM) and N-desisopropyl metoprolol (DIM) were 90.37 ± 2.69, 33.32 ± 1.92, 16.93 ± 1.70 and 7.96 ± 0.94 ng/mL, respectively.",An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006091/),[ng] / [ml],33.32,202306,DB00264,Metoprolol
,27006091,peak concentrations of unbound plasma concentration,"The peak concentrations of unbound plasma concentration of MET, α-hydroxy metoprolol (HM), O-desmethyl metoprolol (ODM) and N-desisopropyl metoprolol (DIM) were 90.37 ± 2.69, 33.32 ± 1.92, 16.93 ± 1.70 and 7.96 ± 0.94 ng/mL, respectively.",An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006091/),[ng] / [ml],16.93,202307,DB00264,Metoprolol
,27006091,peak concentrations of unbound plasma concentration,"The peak concentrations of unbound plasma concentration of MET, α-hydroxy metoprolol (HM), O-desmethyl metoprolol (ODM) and N-desisopropyl metoprolol (DIM) were 90.37 ± 2.69, 33.32 ± 1.92, 16.93 ± 1.70 and 7.96 ± 0.94 ng/mL, respectively.",An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006091/),[ng] / [ml],7.96,202308,DB00264,Metoprolol
,23985694,hepatic extraction ratio,"Metoprolol has an intermediate hepatic extraction ratio in rats (0.586-0.617), and it is assumed that the liver is exclusively responsible for metoprolol metabolism.",Faster non-renal clearance of metoprolol in streptozotocin-induced diabetes mellitus rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23985694/),,0.586-0.617,202473,DB00264,Metoprolol
,29676238,C,"For d-nebivolol, Cmax, Tmax and AUC0-48 were, on average, 5.9, 2.7 and 15.0 larger in PMs.",Effect of CYP2D6 Poor Metabolizer Phenotype on Stereoselective Nebivolol Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29676238/),,5.9,202498,DB00264,Metoprolol
,29676238,Tmax,"For d-nebivolol, Cmax, Tmax and AUC0-48 were, on average, 5.9, 2.7 and 15.0 larger in PMs.",Effect of CYP2D6 Poor Metabolizer Phenotype on Stereoselective Nebivolol Pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29676238/),,2,202499,DB00264,Metoprolol
,19188036,flow rate,"The chromatographic separation was achieved using an isocratic mobile phase consisting of a mixture of acetonitrile and 0.5% formic acid (90:10 (v/v), pH 3.5) flowing through C18 column at a flow rate of 0.2ml/min.",Chromatography-tandem mass spectrometry method for the simultaneous quantitation of metoprolol succinate and simvastatin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188036/),[ml] / [min],0.2,203269,DB00264,Metoprolol
,19188036,m,"Ions were monitored in positive mode and the mass transitions measured were m/z 268.1-->m/z 103.2, m/z 441.3-->m/z 325.1 and m/z 260.0-->m/z 129.5 for MET, SIM and WIS, respectively.",Chromatography-tandem mass spectrometry method for the simultaneous quantitation of metoprolol succinate and simvastatin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188036/),,268.1,203270,DB00264,Metoprolol
,7408406,clearance,"Oral propranolol, 40 mg every 6 hr, induced a fall in theophylline clearance from 0.0464 +/- 0.0294 +/- 0.0129 l/kg/hr (p < 0.001).",Effects of metoprolol and propranolol on theophylline elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408406/),[l] / [h·kg],0.0464,207056,DB00264,Metoprolol
,22718748,recovery,The mean recovery of atenolol was 98.4% for plasma.,HPLC method for determination of atenolol in human plasma and application to a pharmacokinetic study in Turkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718748/),%,98.4,210188,DB00264,Metoprolol
,22718748,limits of detection,"The limits of detection and quantification of atenolol were 1.5 and 5 ng/mL, respectively.",HPLC method for determination of atenolol in human plasma and application to a pharmacokinetic study in Turkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718748/),[ng] / [ml],1.5,210189,DB00264,Metoprolol
,22718748,limits of detection,"The limits of detection and quantification of atenolol were 1.5 and 5 ng/mL, respectively.",HPLC method for determination of atenolol in human plasma and application to a pharmacokinetic study in Turkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718748/),[ng] / [ml],5,210190,DB00264,Metoprolol
,2439812,elimination half-life,"In pharmacokinetic terms, however, these drugs show no pronounced difference in their elimination half-life (ranging between 4 and 8 h).",Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439812/),h,4 and 8,210689,DB00264,Metoprolol
,21595025,flow rate,"Separation of analytes was achieved on an ODS column (100 mm length × 2.1 mm id, 3 μm) by a gradient elution with 10 mM formic acid and methanol by varying their proportion at a flow rate of 0.2 mL/min.",A highly sensitive LC-MS/MS method capable of simultaneously quantitating celiprolol and atenolol in human plasma for a cassette cold-microdosing study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21595025/),[ml] / [min],0.2,211812,DB00264,Metoprolol
,18384443,K(i),"Imatinib, a tyrosine kinase inhibitor, exhibits a competitive inhibition on the CYP450 2D6 isozyme with a K(i) value of 7.5 microm.","Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384443/),μm,7.5,212302,DB00264,Metoprolol
,18384443,AUC,"In the presence of 400 mg twice daily imatinib, the mean metoprolol AUC was increased by 17% in IMs (from 1190 to 1390 ng ml(-1) h), and 24% in EMs (from 660 to 818 ng ml(-1) h).","Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384443/),[h·ng] / [ml],1190 to 1390,212303,DB00264,Metoprolol
,18384443,AUC,"In the presence of 400 mg twice daily imatinib, the mean metoprolol AUC was increased by 17% in IMs (from 1190 to 1390 ng ml(-1) h), and 24% in EMs (from 660 to 818 ng ml(-1) h).","Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384443/),[h·ng] / [ml],660 to 818,212304,DB00264,Metoprolol
,18384443,oral clearance,"The oral clearance of imatinib was 11.0 +/- 2.0 l h(-1) and 11.8 +/- 4.1 l h(-1) for CYP2D6 IMs and EMs, respectively.","Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384443/),[l] / [h],11.0,212305,DB00264,Metoprolol
,18384443,oral clearance,"The oral clearance of imatinib was 11.0 +/- 2.0 l h(-1) and 11.8 +/- 4.1 l h(-1) for CYP2D6 IMs and EMs, respectively.","Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384443/),[l] / [h],11.8,212306,DB00264,Metoprolol
,7660794,recoveries,The mean recoveries were 79.35% to 95.72%.,[Methodological study on the determination of naftopidil concentration in biological samples by HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7660794/),%,79.35,214447,DB00264,Metoprolol
,7660794,recoveries,The mean recoveries were 79.35% to 95.72%.,[Methodological study on the determination of naftopidil concentration in biological samples by HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7660794/),%,95.72,214448,DB00264,Metoprolol
,22271587,quantification limit,The quantification limit was 0.2 ng ml(-1) for both enantiomers in plasma.,Analysis of carvedilol enantiomers in human plasma using chiral stationary phase column and liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271587/),[ng] / [ml],0.2,221107,DB00264,Metoprolol
,22271587,AUC(0-∞),The results showed a higher plasma concentration of (+)-(R)-carvedilol (AUC(0-∞) 205.52 vs.,Analysis of carvedilol enantiomers in human plasma using chiral stationary phase column and liquid chromatography with tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271587/),,205.52,221108,DB00264,Metoprolol
,22237133,flow rate of the mobile phase,"The flow rate of the mobile phase was 250μL/min and the retention times of 4-HAT, N-DAT and internal standard (IS, metoprolol) were 0.9, 1.0 and 1.0min, respectively.",Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22237133/),[μl] / [min],250,222850,DB00264,Metoprolol
,22237133,retention times,"The flow rate of the mobile phase was 250μL/min and the retention times of 4-HAT, N-DAT and internal standard (IS, metoprolol) were 0.9, 1.0 and 1.0min, respectively.",Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22237133/),min,0.9,222851,DB00264,Metoprolol
,22237133,retention times,"The flow rate of the mobile phase was 250μL/min and the retention times of 4-HAT, N-DAT and internal standard (IS, metoprolol) were 0.9, 1.0 and 1.0min, respectively.",Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22237133/),min,1.0,222852,DB00264,Metoprolol
,2434747,terminal elimination half life (t1/2),"After intravenous (i.v.) administration of 50 mg of the drug, there was a biexponential decline in plasma levels with a terminal elimination half life (t1/2) of 1.9 h (range 1.4-2.3 h) and a total apparent volume of distribution at equilibrium of 62 L.",Pharmacokinetics and concentration--effect relationships of bevantolol (CI-775) in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2434747/),h,1.9,223465,DB00264,Metoprolol
,2434747,total apparent volume of distribution at equilibrium,"After intravenous (i.v.) administration of 50 mg of the drug, there was a biexponential decline in plasma levels with a terminal elimination half life (t1/2) of 1.9 h (range 1.4-2.3 h) and a total apparent volume of distribution at equilibrium of 62 L.",Pharmacokinetics and concentration--effect relationships of bevantolol (CI-775) in normal volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2434747/),l,62,223466,DB00264,Metoprolol
,2434747,bioavailability,"After oral administration of the same dose, the bioavailability averaged 57% (range 26-98%) and peak plasma levels varied over a threefold range.",Pharmacokinetics and concentration--effect relationships of bevantolol (CI-775) in normal volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2434747/),%,57,223467,DB00264,Metoprolol
,31467909,flow rate,The flow rate was 0.3 mL/min.,A High Throughput HPLC-MS/MS Method for Antihypertensive Drugs Determination in Plasma and Its Application on Pharmacokinetic Interaction Study with Shuxuetong Injection in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31467909/),[ml] / [min],0.3,224280,DB00264,Metoprolol
,22695883,recoveries,The recoveries ranged from 67.5% to 98.5%.,"UPLC-MS-MS method for simultaneous determination of caffeine, tolbutamide, metoprolol, and dapsone in rat plasma and its application to cytochrome P450 activity study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22695883/),%,67.5,224839,DB00264,Metoprolol
,22695883,recoveries,The recoveries ranged from 67.5% to 98.5%.,"UPLC-MS-MS method for simultaneous determination of caffeine, tolbutamide, metoprolol, and dapsone in rat plasma and its application to cytochrome P450 activity study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22695883/),%,98.5,224840,DB00264,Metoprolol
,1687016,R/S ratio,The hepatic clearance of metoprolol was slightly (S)-enantioselective (R/S ratio = 0.89 +/- 0.04) in control dogs.,Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687016/),,0.89,226297,DB00264,Metoprolol
,1687016,R/S ratio,"Inhibition of hepatic clearance of metoprolol by verapamil was selective towards (S)-metoprolol, such that the enantioselectivity in hepatic clearance toward (S)-metoprolol disappeared following verapamil co-administration (R/S ratio = 1.01 +/- 0.05).",Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687016/),,1.01,226298,DB00264,Metoprolol
,28565860,entrapment efficiency,"The present methodology achieved an entrapment efficiency of 83.2%, with 96.1% of drug released in vitro in 18 h, and the release was close to linear over a 12-h period.",Development of a sustained-release microcapsule for delivery of metoprolol succinate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28565860/),%,83.2,226432,DB00264,Metoprolol
,18043911,areas under the concentration-time curve (AUC),"Following the administration of paroxetine, mean metoprolol areas under the concentration-time curve (AUC) increased (1064 +/- 1213 to 4476 +/- 2821 nM x h/mg per kg, P = 0.0001), while metabolite AUCs decreased (1492 +/- 872 to 348 +/- 279 n M x h/mg per kg, P < 0.0001), with an increase of metabolic ratios (MR) (0.9 +/- 1.3 to 26 +/- 29; P < 0.0001).",Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),[h·nM] / [kg·mg],1064,229786,DB00264,Metoprolol
,18043911,areas under the concentration-time curve (AUC),"Following the administration of paroxetine, mean metoprolol areas under the concentration-time curve (AUC) increased (1064 +/- 1213 to 4476 +/- 2821 nM x h/mg per kg, P = 0.0001), while metabolite AUCs decreased (1492 +/- 872 to 348 +/- 279 n M x h/mg per kg, P < 0.0001), with an increase of metabolic ratios (MR) (0.9 +/- 1.3 to 26 +/- 29; P < 0.0001).",Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),[h·nM] / [kg·mg],4476,229787,DB00264,Metoprolol
,18043911,AUCs,"Following the administration of paroxetine, mean metoprolol areas under the concentration-time curve (AUC) increased (1064 +/- 1213 to 4476 +/- 2821 nM x h/mg per kg, P = 0.0001), while metabolite AUCs decreased (1492 +/- 872 to 348 +/- 279 n M x h/mg per kg, P < 0.0001), with an increase of metabolic ratios (MR) (0.9 +/- 1.3 to 26 +/- 29; P < 0.0001).",Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),[M·h·n] / [kg·mg],1492,229788,DB00264,Metoprolol
,18043911,AUCs,"Following the administration of paroxetine, mean metoprolol areas under the concentration-time curve (AUC) increased (1064 +/- 1213 to 4476 +/- 2821 nM x h/mg per kg, P = 0.0001), while metabolite AUCs decreased (1492 +/- 872 to 348 +/- 279 n M x h/mg per kg, P < 0.0001), with an increase of metabolic ratios (MR) (0.9 +/- 1.3 to 26 +/- 29; P < 0.0001).",Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),[M·h·n] / [kg·mg],348,229789,DB00264,Metoprolol
,18043911,metabolic ratios (MR),"Following the administration of paroxetine, mean metoprolol areas under the concentration-time curve (AUC) increased (1064 +/- 1213 to 4476 +/- 2821 nM x h/mg per kg, P = 0.0001), while metabolite AUCs decreased (1492 +/- 872 to 348 +/- 279 n M x h/mg per kg, P < 0.0001), with an increase of metabolic ratios (MR) (0.9 +/- 1.3 to 26 +/- 29; P < 0.0001).",Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),,0.9,229790,DB00264,Metoprolol
,18043911,metabolic ratios (MR),"Following the administration of paroxetine, mean metoprolol areas under the concentration-time curve (AUC) increased (1064 +/- 1213 to 4476 +/- 2821 nM x h/mg per kg, P = 0.0001), while metabolite AUCs decreased (1492 +/- 872 to 348 +/- 279 n M x h/mg per kg, P < 0.0001), with an increase of metabolic ratios (MR) (0.9 +/- 1.3 to 26 +/- 29; P < 0.0001).",Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),,26,229791,DB00264,Metoprolol
,18043911,area under the HR versus time curve (AUEC),Mean area under the HR versus time curve (AUEC) decreased (835 +/- 88 to 728 +/- 84 beats x h/min; P = 0.0007).,Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),[beats·h] / [min],835,229792,DB00264,Metoprolol
,18043911,area under the HR versus time curve (AUEC),Mean area under the HR versus time curve (AUEC) decreased (835 +/- 88 to 728 +/- 84 beats x h/min; P = 0.0007).,Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043911/),[beats·h] / [min],728,229793,DB00264,Metoprolol
,30443705,"Cav,ss","Clinically relevant nitisinone steady-state concentrations were reached after 12 days: mean Cav,ss of 94.08 μM.","Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30443705/),μM,94.08,230404,DB00264,Metoprolol
,4005127,initial release rates,"Plasma concentrations and haemodynamic effects at rest and during exercise have been measured in six healthy volunteers after single oral dosing with two Oros drug delivery systems containing 190 mg metoprolol fumarate but with initial release rates of 14 and 19 mg/h, respectively.",Comparison of single-dose pharmacokinetic and pharmacodynamic properties of two metoprolol Oros systems with different initial zero-order release rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4005127/),[mg] / [h],14,231874,DB00264,Metoprolol
,4005127,initial release rates,"Plasma concentrations and haemodynamic effects at rest and during exercise have been measured in six healthy volunteers after single oral dosing with two Oros drug delivery systems containing 190 mg metoprolol fumarate but with initial release rates of 14 and 19 mg/h, respectively.",Comparison of single-dose pharmacokinetic and pharmacodynamic properties of two metoprolol Oros systems with different initial zero-order release rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4005127/),[mg] / [h],19,231875,DB00264,Metoprolol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],72,234919,DB00264,Metoprolol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],87,234920,DB00264,Metoprolol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],44,234921,DB00264,Metoprolol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],0.2,234922,DB00264,Metoprolol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],167,234923,DB00264,Metoprolol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],114,234924,DB00264,Metoprolol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],96,234925,DB00264,Metoprolol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],24,234926,DB00264,Metoprolol
,25753317,flow rate,"The plasma samples were prepared by protein precipitation, then the separation of the analytes was performed on an Agilent HC-C18 column (4.6 × 250 mm, 5 µm) at a flow rate of 1.0 mL/min, and post-column splitting (1:4) was used to give optimal interface flow rates (0.2 mL/min) for MS detection; the total run time was 8.5 min.","Development of a LC-MS/MS method for simultaneous determination of metoprolol and its metabolites, α-hydroxymetoprolol and O-desmethylmetoprolol, in rat plasma: application to the herb-drug interaction study of metoprolol and breviscapine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25753317/),,1,235511,DB00264,Metoprolol
,25753317,interface flow rates,"The plasma samples were prepared by protein precipitation, then the separation of the analytes was performed on an Agilent HC-C18 column (4.6 × 250 mm, 5 µm) at a flow rate of 1.0 mL/min, and post-column splitting (1:4) was used to give optimal interface flow rates (0.2 mL/min) for MS detection; the total run time was 8.5 min.","Development of a LC-MS/MS method for simultaneous determination of metoprolol and its metabolites, α-hydroxymetoprolol and O-desmethylmetoprolol, in rat plasma: application to the herb-drug interaction study of metoprolol and breviscapine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25753317/),[ml] / [min],0.2,235512,DB00264,Metoprolol
,25753317,total run time,"The plasma samples were prepared by protein precipitation, then the separation of the analytes was performed on an Agilent HC-C18 column (4.6 × 250 mm, 5 µm) at a flow rate of 1.0 mL/min, and post-column splitting (1:4) was used to give optimal interface flow rates (0.2 mL/min) for MS detection; the total run time was 8.5 min.","Development of a LC-MS/MS method for simultaneous determination of metoprolol and its metabolites, α-hydroxymetoprolol and O-desmethylmetoprolol, in rat plasma: application to the herb-drug interaction study of metoprolol and breviscapine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25753317/),min,8.5,235513,DB00264,Metoprolol
,465277,half-life,"The average half-life, 4.4 +/- 0.9 h, is about the same as previously observed for separate doses of this drug.",Bioavailability and disposition of metoprolol and hydrochlorothiazide combined in one tablet and of separate doses of hydrochlorothiazide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/465277/),h,4.4,237730,DB00264,Metoprolol
,26461463,apparent oral clearance,"Using paired analysis, mean metoprolol apparent oral clearance was significantly higher in mid-pregnancy (361 ± 223 L/h, n = 5, P < .05) and late pregnancy (568 ± 273 L/h, n = 8, P < .05) compared with ≥3 months postpartum (200 ± 131 and 192 ± 98 L/h, respectively).",Pharmacokinetics of metoprolol during pregnancy and lactation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26461463/),[l] / [h],361,237862,DB00264,Metoprolol
,26461463,apparent oral clearance,"Using paired analysis, mean metoprolol apparent oral clearance was significantly higher in mid-pregnancy (361 ± 223 L/h, n = 5, P < .05) and late pregnancy (568 ± 273 L/h, n = 8, P < .05) compared with ≥3 months postpartum (200 ± 131 and 192 ± 98 L/h, respectively).",Pharmacokinetics of metoprolol during pregnancy and lactation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26461463/),[l] / [h],568,237863,DB00264,Metoprolol
,26461463,apparent oral clearance,"Using paired analysis, mean metoprolol apparent oral clearance was significantly higher in mid-pregnancy (361 ± 223 L/h, n = 5, P < .05) and late pregnancy (568 ± 273 L/h, n = 8, P < .05) compared with ≥3 months postpartum (200 ± 131 and 192 ± 98 L/h, respectively).",Pharmacokinetics of metoprolol during pregnancy and lactation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26461463/),[l] / [h],200,237864,DB00264,Metoprolol
,26461463,apparent oral clearance,"Using paired analysis, mean metoprolol apparent oral clearance was significantly higher in mid-pregnancy (361 ± 223 L/h, n = 5, P < .05) and late pregnancy (568 ± 273 L/h, n = 8, P < .05) compared with ≥3 months postpartum (200 ± 131 and 192 ± 98 L/h, respectively).",Pharmacokinetics of metoprolol during pregnancy and lactation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26461463/),[l] / [h],192,237865,DB00264,Metoprolol
,23728524,half-life,Mean metoprolol half-life increased from 2.96 to 4.11 h.,"The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23728524/),h,2.96,240571,DB00264,Metoprolol
,23728524,half-life,Mean metoprolol half-life increased from 2.96 to 4.11 h.,"The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23728524/),h,4,240572,DB00264,Metoprolol
,23728524,half-life,Mean desipramine half-life increased from 19.5 to 35.8 h.,"The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23728524/),h,19.5,240573,DB00264,Metoprolol
,23728524,half-life,Mean desipramine half-life increased from 19.5 to 35.8 h.,"The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23728524/),h,35,240574,DB00264,Metoprolol
>,23607649,f2,Stability studies showed no significant difference (f2>50) in MPL release profile after three months of storage period at 25 ± 2°C/60 ± 5% RH and 40 ± 2°C/75 ± 5% RH.,"Compritol®888 ATO a lipid excipient for sustained release of highly water soluble active: formulation, scale-up and IVIVC study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23607649/),,50,240800,DB00264,Metoprolol
,10223777,area under plasma concentration curves (AUC),"The area under plasma concentration curves (AUC) of S-metoprolol was 1411+/-116 (mean +/- SEM, n = 16), 1899+/-120 (n = 12), and 3588+/-435 (n = 12) nmol x hr/L for homozygous C188, heterozygous C/T188, and homozygous T188 subjects, respectively.",Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223777/),[h·nM] / [l],1411,242133,DB00264,Metoprolol
,10223777,area under plasma concentration curves (AUC),"The area under plasma concentration curves (AUC) of S-metoprolol was 1411+/-116 (mean +/- SEM, n = 16), 1899+/-120 (n = 12), and 3588+/-435 (n = 12) nmol x hr/L for homozygous C188, heterozygous C/T188, and homozygous T188 subjects, respectively.",Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223777/),[h·nM] / [l],1899,242134,DB00264,Metoprolol
,10223777,area under plasma concentration curves (AUC),"The area under plasma concentration curves (AUC) of S-metoprolol was 1411+/-116 (mean +/- SEM, n = 16), 1899+/-120 (n = 12), and 3588+/-435 (n = 12) nmol x hr/L for homozygous C188, heterozygous C/T188, and homozygous T188 subjects, respectively.",Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223777/),[h·nM] / [l],3588,242135,DB00264,Metoprolol
,1801888,peak plasma concentration,Intravenously administered metoprolol resulted in a higher peak plasma concentration of metoprolol (382 +/- 52 nmol/l) than coronary sinus retroinfusion (276 +/- 47 nmol/l).,Pharmacokinetic analysis of coronary sinus retroinfusion in pigs. Ischemic myocardial concentrations in the left circumflex coronary arterial area using metoprolol as a tracer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1801888/),[nM] / [l],382,242186,DB00264,Metoprolol
,1801888,peak plasma concentration,Intravenously administered metoprolol resulted in a higher peak plasma concentration of metoprolol (382 +/- 52 nmol/l) than coronary sinus retroinfusion (276 +/- 47 nmol/l).,Pharmacokinetic analysis of coronary sinus retroinfusion in pigs. Ischemic myocardial concentrations in the left circumflex coronary arterial area using metoprolol as a tracer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1801888/),[nM] / [l],276,242187,DB00264,Metoprolol
,2023110,extraction ratio through the pulmonary circulation (Ep),"Results of the curve fitting showed that the single-pass extraction ratio through the pulmonary circulation (Ep) of metoprolol was about 0.2, whereas that of cephalexin was negligible.",Analysis of arterial-venous blood concentration difference of drugs based on recirculatory theory with fast inverse Laplace transform (FILT). ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023110/),,0.2,243847,DB00264,Metoprolol
,2023110,mean transit times through the pulmonary circulation (tp),"The mean transit times through the pulmonary circulation (tp) of metoprolol and cephalexin were both about 0.5 min, which is small.",Analysis of arterial-venous blood concentration difference of drugs based on recirculatory theory with fast inverse Laplace transform (FILT). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023110/),min,0.5,243848,DB00264,Metoprolol
,2023110,extraction ratios through the systemic circulation (Es),"The single-pass extraction ratios through the systemic circulation (Es) of metoprolol and cephalexin were both about 0.1, and the mean transit times through the systemic circulation (ts) were 11.5 min and 8.2 min, respectively.",Analysis of arterial-venous blood concentration difference of drugs based on recirculatory theory with fast inverse Laplace transform (FILT). ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023110/),,0.1,243849,DB00264,Metoprolol
,2023110,transit times through the systemic circulation (ts),"The single-pass extraction ratios through the systemic circulation (Es) of metoprolol and cephalexin were both about 0.1, and the mean transit times through the systemic circulation (ts) were 11.5 min and 8.2 min, respectively.",Analysis of arterial-venous blood concentration difference of drugs based on recirculatory theory with fast inverse Laplace transform (FILT). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023110/),min,11.5,243850,DB00264,Metoprolol
,2023110,transit times through the systemic circulation (ts),"The single-pass extraction ratios through the systemic circulation (Es) of metoprolol and cephalexin were both about 0.1, and the mean transit times through the systemic circulation (ts) were 11.5 min and 8.2 min, respectively.",Analysis of arterial-venous blood concentration difference of drugs based on recirculatory theory with fast inverse Laplace transform (FILT). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023110/),min,8.2,243851,DB00264,Metoprolol
,30048731,recoveries,The intra and inter-assay accuracy and precision of the method were within ± 14.9% and the recoveries ranged from 83.2% to 106.1%.,"Effects of Baoyuan decoction, a traditional Chinese medicine formula, on the activities and mRNA expression of seven CYP isozymes in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30048731/),%,83.2,244934,DB00264,Metoprolol
,30048731,recoveries,The intra and inter-assay accuracy and precision of the method were within ± 14.9% and the recoveries ranged from 83.2% to 106.1%.,"Effects of Baoyuan decoction, a traditional Chinese medicine formula, on the activities and mRNA expression of seven CYP isozymes in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30048731/),%,106.1,244935,DB00264,Metoprolol
,15735613,DeltaCp(ave),"Mean DeltaCp(ave) and Cp(ave)/Cp'(ave) were 7.9 ng/mL (SD, 10.7) and 0.6 (SD, 0.3), respectively.",Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735613/),[ng] / [ml],7.9,246400,DB00264,Metoprolol
,15735613,Cp(ave)/Cp'(ave),"Mean DeltaCp(ave) and Cp(ave)/Cp'(ave) were 7.9 ng/mL (SD, 10.7) and 0.6 (SD, 0.3), respectively.",Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735613/),,0.6,246401,DB00264,Metoprolol
,2591419,partition,The partition of metoprolol between blood cells and plasma averaged 1.14 in both conditions.,Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591419/),,1.14,247094,DB00264,Metoprolol
,2591419,Plasma protein binding,"Plasma protein binding, concentration-independent, was 32% and 17% in normal and pathological status, respectively.",Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591419/),%,32,247095,DB00264,Metoprolol
,2591419,Plasma protein binding,"Plasma protein binding, concentration-independent, was 32% and 17% in normal and pathological status, respectively.",Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591419/),%,17,247096,DB00264,Metoprolol
,2591419,terminal elimination half-life,"With normal liver function the terminal elimination half-life for the drug was 0.54-0.96 h, rising to 1.0-2.1 h in liver failure.",Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591419/),h,0.54-0.96,247097,DB00264,Metoprolol
,2591419,terminal elimination half-life,"With normal liver function the terminal elimination half-life for the drug was 0.54-0.96 h, rising to 1.0-2.1 h in liver failure.",Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591419/),h,1.0-2.1,247098,DB00264,Metoprolol
,2591419,total plasma drug clearance,"Differences of the same order were observed for total plasma drug clearance (average 3.7 vs 1.5 1/h/kg), MRT (0.77 vs 1.92 h), AUC (0.9 vs 2.2 mg h/l) and k10 (3.17 vs 1.80 h-1).",Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591419/),[1] / [h·kg],3.7,247099,DB00264,Metoprolol
,2591419,total plasma drug clearance,"Differences of the same order were observed for total plasma drug clearance (average 3.7 vs 1.5 1/h/kg), MRT (0.77 vs 1.92 h), AUC (0.9 vs 2.2 mg h/l) and k10 (3.17 vs 1.80 h-1).",Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591419/),[1] / [h·kg],1.5,247100,DB00264,Metoprolol
,2591419,MRT,"Differences of the same order were observed for total plasma drug clearance (average 3.7 vs 1.5 1/h/kg), MRT (0.77 vs 1.92 h), AUC (0.9 vs 2.2 mg h/l) and k10 (3.17 vs 1.80 h-1).",Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591419/),h,0.77,247101,DB00264,Metoprolol
,2591419,MRT,"Differences of the same order were observed for total plasma drug clearance (average 3.7 vs 1.5 1/h/kg), MRT (0.77 vs 1.92 h), AUC (0.9 vs 2.2 mg h/l) and k10 (3.17 vs 1.80 h-1).",Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591419/),h,1.92,247102,DB00264,Metoprolol
,2591419,AUC,"Differences of the same order were observed for total plasma drug clearance (average 3.7 vs 1.5 1/h/kg), MRT (0.77 vs 1.92 h), AUC (0.9 vs 2.2 mg h/l) and k10 (3.17 vs 1.80 h-1).",Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591419/),[h·mg] / [l],0.9,247103,DB00264,Metoprolol
,2591419,AUC,"Differences of the same order were observed for total plasma drug clearance (average 3.7 vs 1.5 1/h/kg), MRT (0.77 vs 1.92 h), AUC (0.9 vs 2.2 mg h/l) and k10 (3.17 vs 1.80 h-1).",Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591419/),[h·mg] / [l],2.2,247104,DB00264,Metoprolol
,2591419,k10,"Differences of the same order were observed for total plasma drug clearance (average 3.7 vs 1.5 1/h/kg), MRT (0.77 vs 1.92 h), AUC (0.9 vs 2.2 mg h/l) and k10 (3.17 vs 1.80 h-1).",Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591419/),1/[h],3.17,247105,DB00264,Metoprolol
,2591419,k10,"Differences of the same order were observed for total plasma drug clearance (average 3.7 vs 1.5 1/h/kg), MRT (0.77 vs 1.92 h), AUC (0.9 vs 2.2 mg h/l) and k10 (3.17 vs 1.80 h-1).",Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591419/),1/[h],1.80,247106,DB00264,Metoprolol
,2591419,unbound plasma concentration,"The mean unbound plasma concentration producing 50% of this reduction was double during liver failure compared to normal condition (0.03 vs 0.07 mg/l), but the temporal aspects of drug equilibration with site of action were similar.",Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591419/),[mg] / [l],0.03,247107,DB00264,Metoprolol
,2591419,unbound plasma concentration,"The mean unbound plasma concentration producing 50% of this reduction was double during liver failure compared to normal condition (0.03 vs 0.07 mg/l), but the temporal aspects of drug equilibration with site of action were similar.",Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591419/),[mg] / [l],0.07,247108,DB00264,Metoprolol
,2702795,Emax,"The predicted Emax for the black group was 52.7 +/- 8.7 beats/min at a metoprolol concentration of 29.8 +/- 6.1 ng/ml, which was higher (p less than 0.05) than that in the white group, i.e., 43.7 +/- 7.3 beats/min at a concentration of 27.6 +/- 9.1 ng/ml.",Racial differences in drug response: isoproterenol effects on heart rate following intravenous metoprolol. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702795/),[beats] / [min],52.7,249620,DB00264,Metoprolol
,2702795,Emax,"The predicted Emax for the black group was 52.7 +/- 8.7 beats/min at a metoprolol concentration of 29.8 +/- 6.1 ng/ml, which was higher (p less than 0.05) than that in the white group, i.e., 43.7 +/- 7.3 beats/min at a concentration of 27.6 +/- 9.1 ng/ml.",Racial differences in drug response: isoproterenol effects on heart rate following intravenous metoprolol. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702795/),[beats] / [min],43.7,249621,DB00264,Metoprolol
> or =,11486824,absolute recoveries,The absolute recoveries for each analyte was > or = 95%.,Enantiomeric separation of metoprolol and alpha-hydroxymetoprolol by liquid chromatography and fluorescence detection using a chiral stationary phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11486824/),%,95,250112,DB00264,Metoprolol
,12474215,Retention times,"Retention times for bisoprolol and metoprolol were 8.7 and 3.2 min, respectively.","Development, validation and analytical error function of two chromatographic methods with fluorimetric detection for the determination of bisoprolol and metoprolol in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12474215/),min,8.7,255292,DB00264,Metoprolol
,12474215,Retention times,"Retention times for bisoprolol and metoprolol were 8.7 and 3.2 min, respectively.","Development, validation and analytical error function of two chromatographic methods with fluorimetric detection for the determination of bisoprolol and metoprolol in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12474215/),min,3.2,255293,DB00264,Metoprolol
,12474215,recovery,Average recovery was 89% for metoprolol and 98% for bisoprolol.,"Development, validation and analytical error function of two chromatographic methods with fluorimetric detection for the determination of bisoprolol and metoprolol in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12474215/),%,89,255294,DB00264,Metoprolol
,12474215,recovery,Average recovery was 89% for metoprolol and 98% for bisoprolol.,"Development, validation and analytical error function of two chromatographic methods with fluorimetric detection for the determination of bisoprolol and metoprolol in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12474215/),%,98,255295,DB00264,Metoprolol
,10848718,area under the plasma concentration-time curve,"Concomitant administration of HCQ increased the bioavailability of metoprolol, as indicated by significant increases in the area under the plasma concentration-time curve (65 +/- 4.6%) and maximal plasma concentrations (72 +/- 6.9%) of metoprolol.",Influence of hydroxychloroquine on the bioavailability of oral metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10848718/),%,65,256387,DB00264,Metoprolol
,10848718,maximal plasma concentrations,"Concomitant administration of HCQ increased the bioavailability of metoprolol, as indicated by significant increases in the area under the plasma concentration-time curve (65 +/- 4.6%) and maximal plasma concentrations (72 +/- 6.9%) of metoprolol.",Influence of hydroxychloroquine on the bioavailability of oral metoprolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10848718/),%,72,256388,DB00264,Metoprolol
,33811,maximal plasma level,"When metoprolol had been administered in a cumulative dose of 150 mg (mean maximal plasma level, 284 nmol/l) prenalterol had to be administered in doses that were twelve times higher than before the beta-blocker in order to induce the same haemodynamic effects.","Haemodynamic effects and pharmacokinetics of a new selective beta1-adrenoceptor agonist, prenalterol, and its interaction with metoprolol in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33811/),[nM] / [l],284,257340,DB00264,Metoprolol
,33811,half life,Prenalterol was rapidly distributed with an average half life of 8 min.,"Haemodynamic effects and pharmacokinetics of a new selective beta1-adrenoceptor agonist, prenalterol, and its interaction with metoprolol in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33811/),min,8,257341,DB00264,Metoprolol
,33811,half life,The overall elimination rate in the post-distributive phase corresponded to an average half life of 2.0 h.,"Haemodynamic effects and pharmacokinetics of a new selective beta1-adrenoceptor agonist, prenalterol, and its interaction with metoprolol in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33811/),h,2.0,257342,DB00264,Metoprolol
,12774293,AUC(0-24),We observed stereo-selectivity in the alpha-hydroxymetoprolol formation favoring the new 1'R chiral center from both metoprolol enantiomers (AUC(0-24) (1'R1'S) = 3.02).,Stereoselective metabolism of metoprolol: enantioselectivity of alpha-hydroxymetoprolol in plasma and urine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12774293/),,3.02,257405,DB00264,Metoprolol
,12774293,AUC(0-24),"(-)-(S)-metoprolol was slightly more alpha-hydroxylated than its antipode (AUC(0-24) (2S/2R) = 1.19), suggesting that this pathway is not responsible for plasma accumulation of this enantiomer in humans.",Stereoselective metabolism of metoprolol: enantioselectivity of alpha-hydroxymetoprolol in plasma and urine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12774293/),,1.19,257406,DB00264,Metoprolol
,29115741,m/,"Quantification was performed in multiple reaction monitoring mode with the transition m/z 372.1 → 316.1 for arotinolol, m/z 268.2 → 116.2 for metoprolol, m/z 409.1 → 238.1 for amlodipine and m/z 413.1 → 238.1 for (S)-amlodipine-d4.",High-throughput LC-MS/MS method with 96-well plate precipitation for the determination of arotinolol and amlodipine in a small volume of rat plasma: Application to a pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29115741/),,268.2,262035,DB00264,Metoprolol
,29115741,m/,"Quantification was performed in multiple reaction monitoring mode with the transition m/z 372.1 → 316.1 for arotinolol, m/z 268.2 → 116.2 for metoprolol, m/z 409.1 → 238.1 for amlodipine and m/z 413.1 → 238.1 for (S)-amlodipine-d4.",High-throughput LC-MS/MS method with 96-well plate precipitation for the determination of arotinolol and amlodipine in a small volume of rat plasma: Application to a pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29115741/),,409.1,262036,DB00264,Metoprolol
,29115741,m/,"Quantification was performed in multiple reaction monitoring mode with the transition m/z 372.1 → 316.1 for arotinolol, m/z 268.2 → 116.2 for metoprolol, m/z 409.1 → 238.1 for amlodipine and m/z 413.1 → 238.1 for (S)-amlodipine-d4.",High-throughput LC-MS/MS method with 96-well plate precipitation for the determination of arotinolol and amlodipine in a small volume of rat plasma: Application to a pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29115741/),,413.1,262037,DB00264,Metoprolol
,29115741,m/,"Quantification was performed in multiple reaction monitoring mode with the transition m/z 372.1 → 316.1 for arotinolol, m/z 268.2 → 116.2 for metoprolol, m/z 409.1 → 238.1 for amlodipine and m/z 413.1 → 238.1 for (S)-amlodipine-d4.",High-throughput LC-MS/MS method with 96-well plate precipitation for the determination of arotinolol and amlodipine in a small volume of rat plasma: Application to a pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29115741/),,238.1,262038,DB00264,Metoprolol
,2693499,half-life,"It has a half-life of 15-18 hours, and is demonstrated to be effective as an antihypertensive agent for 24-30 hours.",Dilevalol: a selective beta-2 adrenergic agonist vasodilator with beta adrenergic blocking activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2693499/),h,15-18,265055,DB00264,Metoprolol
,2312775,"maximal plasma concentration, Cmax","The maximal plasma concentration, Cmax, was significantly lower after metoprolol CR/ZOK compared to CT after all doses--the most pronounced difference being observed after the 100 mg dose when both preparations were given once daily (145 nmol/L vs 606 nmol/L) and the least difference after the 400 mg dose when metoprolol CT was given every 6 hours (837 nmol/L vs 1111 nmol/L).",Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312775/),[nM] / [l],145,266188,DB00264,Metoprolol
,2312775,"maximal plasma concentration, Cmax","The maximal plasma concentration, Cmax, was significantly lower after metoprolol CR/ZOK compared to CT after all doses--the most pronounced difference being observed after the 100 mg dose when both preparations were given once daily (145 nmol/L vs 606 nmol/L) and the least difference after the 400 mg dose when metoprolol CT was given every 6 hours (837 nmol/L vs 1111 nmol/L).",Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312775/),[nM] / [l],606,266189,DB00264,Metoprolol
,2312775,"maximal plasma concentration, Cmax","The maximal plasma concentration, Cmax, was significantly lower after metoprolol CR/ZOK compared to CT after all doses--the most pronounced difference being observed after the 100 mg dose when both preparations were given once daily (145 nmol/L vs 606 nmol/L) and the least difference after the 400 mg dose when metoprolol CT was given every 6 hours (837 nmol/L vs 1111 nmol/L).",Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312775/),[nM] / [l],837,266190,DB00264,Metoprolol
,2312775,"maximal plasma concentration, Cmax","The maximal plasma concentration, Cmax, was significantly lower after metoprolol CR/ZOK compared to CT after all doses--the most pronounced difference being observed after the 100 mg dose when both preparations were given once daily (145 nmol/L vs 606 nmol/L) and the least difference after the 400 mg dose when metoprolol CT was given every 6 hours (837 nmol/L vs 1111 nmol/L).",Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312775/),[nM] / [l],1111,266191,DB00264,Metoprolol
,2312775,maximal plasma concentration,The maximal plasma concentration occurred later after metoprolol CR/ZOK than CT in all studies (median 2.5-4.1 hours vs 1.0-1.2 hours).,Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312775/),h,2.5-4.1,266192,DB00264,Metoprolol
,2312775,maximal plasma concentration,The maximal plasma concentration occurred later after metoprolol CR/ZOK than CT in all studies (median 2.5-4.1 hours vs 1.0-1.2 hours).,Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312775/),h,1.0-1.2,266193,DB00264,Metoprolol
,2312775,CminS,"The trough plasma concentration, Cmin, was significantly higher after 100 mg metoprolol CR/ZOK compared to CT dosed once daily; CminS were comparable between the two preparations in the 200 mg and 300 mg studies and lower after metoprolol CR/ZOK in the 400 mg study (278 nmol/L vs 469 nmol/L).",Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312775/),[nM] / [l],278,266194,DB00264,Metoprolol
,2312775,CminS,"The trough plasma concentration, Cmin, was significantly higher after 100 mg metoprolol CR/ZOK compared to CT dosed once daily; CminS were comparable between the two preparations in the 200 mg and 300 mg studies and lower after metoprolol CR/ZOK in the 400 mg study (278 nmol/L vs 469 nmol/L).",Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312775/),[nM] / [l],469,266195,DB00264,Metoprolol
,2312775,relative bioavailability,In all four studies the AUCs were significantly lower after metoprolol CR/ZOK compared to CT with the mean relative bioavailability being approximately similar (73-84%).,Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312775/),%,73-84,266196,DB00264,Metoprolol
,2566475,CSF/plasma ratio,The concentration of atenolol declined more slowly in CSF than in blood plasma and the CSF/plasma ratio of atenolol (after iv administration for 7 days) increased from 0.08 +/- 0.02 (2 hr after dose) to 0.83 +/- 0.14 (24 hr after dose) (mean +/- SD).,Central nervous system kinetics of atenolol and metoprolol in the dog during long term treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566475/),,0.08,266297,DB00264,Metoprolol
,2566475,CSF/plasma ratio,The concentration of atenolol declined more slowly in CSF than in blood plasma and the CSF/plasma ratio of atenolol (after iv administration for 7 days) increased from 0.08 +/- 0.02 (2 hr after dose) to 0.83 +/- 0.14 (24 hr after dose) (mean +/- SD).,Central nervous system kinetics of atenolol and metoprolol in the dog during long term treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566475/),,0.83,266298,DB00264,Metoprolol
,2566475,CSF/plasma ratio,The CSF/plasma ratio 24 hr after an iv dose was 0.48 +/- 0.12 on day 1 and 0.83 +/- 0.14 on day 7.,Central nervous system kinetics of atenolol and metoprolol in the dog during long term treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566475/),,0.48,266299,DB00264,Metoprolol
,2566475,CSF/plasma ratio,The CSF/plasma ratio 24 hr after an iv dose was 0.48 +/- 0.12 on day 1 and 0.83 +/- 0.14 on day 7.,Central nervous system kinetics of atenolol and metoprolol in the dog during long term treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566475/),,0.83,266300,DB00264,Metoprolol
,2566475,CSF/plasma ratio,"After 7 days of oral treatment, the CSF/plasma ratio of metoprolol 24 hr after dosing was 0.81 +/- 0.10.",Central nervous system kinetics of atenolol and metoprolol in the dog during long term treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566475/),,0.81,266301,DB00264,Metoprolol
,27771456,Cmax,"After being pretreated with AF in rats, the plasma concentrations of dextrorphan and hydroxymetoprolol significantly decreased, with Cmax going from 79.44 to 29.96 and 151.18 to 83.39hng/mL (P<0.05), AUCall from 167.27 to 62.25 and 347.68 to 223.24hng/mL (P<0.05), and AUCinf from 183.39 to 84.76 and 350.59 to 234.57hng/mL (P<0.05), respectively, in comparison with those of untreated rats.",Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),[hng] / [ml],79.44 to 29.96,268837,DB00264,Metoprolol
,27771456,Cmax,"After being pretreated with AF in rats, the plasma concentrations of dextrorphan and hydroxymetoprolol significantly decreased, with Cmax going from 79.44 to 29.96 and 151.18 to 83.39hng/mL (P<0.05), AUCall from 167.27 to 62.25 and 347.68 to 223.24hng/mL (P<0.05), and AUCinf from 183.39 to 84.76 and 350.59 to 234.57hng/mL (P<0.05), respectively, in comparison with those of untreated rats.",Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),[hng] / [ml],151,268838,DB00264,Metoprolol
,27771456,AUCall,"After being pretreated with AF in rats, the plasma concentrations of dextrorphan and hydroxymetoprolol significantly decreased, with Cmax going from 79.44 to 29.96 and 151.18 to 83.39hng/mL (P<0.05), AUCall from 167.27 to 62.25 and 347.68 to 223.24hng/mL (P<0.05), and AUCinf from 183.39 to 84.76 and 350.59 to 234.57hng/mL (P<0.05), respectively, in comparison with those of untreated rats.",Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),[hng] / [ml],167.27 to 62.25,268839,DB00264,Metoprolol
,27771456,AUCall,"After being pretreated with AF in rats, the plasma concentrations of dextrorphan and hydroxymetoprolol significantly decreased, with Cmax going from 79.44 to 29.96 and 151.18 to 83.39hng/mL (P<0.05), AUCall from 167.27 to 62.25 and 347.68 to 223.24hng/mL (P<0.05), and AUCinf from 183.39 to 84.76 and 350.59 to 234.57hng/mL (P<0.05), respectively, in comparison with those of untreated rats.",Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),[hng] / [ml],347.68 to 223.24,268840,DB00264,Metoprolol
,27771456,AUCinf,"After being pretreated with AF in rats, the plasma concentrations of dextrorphan and hydroxymetoprolol significantly decreased, with Cmax going from 79.44 to 29.96 and 151.18 to 83.39hng/mL (P<0.05), AUCall from 167.27 to 62.25 and 347.68 to 223.24hng/mL (P<0.05), and AUCinf from 183.39 to 84.76 and 350.59 to 234.57hng/mL (P<0.05), respectively, in comparison with those of untreated rats.",Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),[hng] / [ml],183.39 to 84.76,268841,DB00264,Metoprolol
,27771456,AUCinf,"After being pretreated with AF in rats, the plasma concentrations of dextrorphan and hydroxymetoprolol significantly decreased, with Cmax going from 79.44 to 29.96 and 151.18 to 83.39hng/mL (P<0.05), AUCall from 167.27 to 62.25 and 347.68 to 223.24hng/mL (P<0.05), and AUCinf from 183.39 to 84.76 and 350.59 to 234.57hng/mL (P<0.05), respectively, in comparison with those of untreated rats.",Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),[hng] / [ml],350.59 to 234.57,268842,DB00264,Metoprolol
,27771456,t1/2,The t1/2 of hydroxymetoprolol significantly increased from 1.14 to 1.99h (P<0.05).,Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),h,1.14,268843,DB00264,Metoprolol
,27771456,t1/2,The t1/2 of hydroxymetoprolol significantly increased from 1.14 to 1.99h (P<0.05).,Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),h,1.99,268844,DB00264,Metoprolol
,27771456,apparent Ki,"The in vitro incubation test showed that AF competitively inhibited the CYP2D6, with apparent Ki value of 0.64µg/mL.",Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),[μg] / [ml],0.64,268845,DB00264,Metoprolol
,2243149,bioavailability,"The bioavailability of the oral dose on day 1 and day 29 was 13% and 12.5%, respectively.",Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),%,13,269502,DB00264,Metoprolol
,2243149,bioavailability,"The bioavailability of the oral dose on day 1 and day 29 was 13% and 12.5%, respectively.",Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),%,12.5,269503,DB00264,Metoprolol
,2243149,terminal plasma half-life (t1/2),The terminal plasma half-life (t1/2) on day 29 was 22 hours and systemic clearance was 490 mL/min on day 1 and 434 mL/min on day 29 (NS).,Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),h,22,269504,DB00264,Metoprolol
,2243149,systemic clearance,The terminal plasma half-life (t1/2) on day 29 was 22 hours and systemic clearance was 490 mL/min on day 1 and 434 mL/min on day 29 (NS).,Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),[ml] / [min],490,269505,DB00264,Metoprolol
,2243149,systemic clearance,The terminal plasma half-life (t1/2) on day 29 was 22 hours and systemic clearance was 490 mL/min on day 1 and 434 mL/min on day 29 (NS).,Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),[ml] / [min],434,269506,DB00264,Metoprolol
,2243149,protein binding,The protein binding determined by equilibrium dialysis in the six patients with the lowest GFR was 99.74% on day 1 and 99.73% on day 29 and did not differ significantly from previously reported values in healthy subjects.,Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),%,99.74,269507,DB00264,Metoprolol
,2243149,protein binding,The protein binding determined by equilibrium dialysis in the six patients with the lowest GFR was 99.74% on day 1 and 99.73% on day 29 and did not differ significantly from previously reported values in healthy subjects.,Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),%,99.73,269508,DB00264,Metoprolol
,19782235,analytical recovery,The analytical recovery of metoprolol from human plasma averaged 91.20%.,Gas chromatography-mass spectrometry method for determination of metoprolol in the patients with hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19782235/),%,91.20,270295,DB00264,Metoprolol
,19782235,limits of detection (LOD),"The limits of detection (LOD) and quantification (LOQ) of metoprolol were 5.0 and 15 ng/ml, respectively.",Gas chromatography-mass spectrometry method for determination of metoprolol in the patients with hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19782235/),[ng] / [ml],5.0,270296,DB00264,Metoprolol
,19782235,quantification (LOQ),"The limits of detection (LOD) and quantification (LOQ) of metoprolol were 5.0 and 15 ng/ml, respectively.",Gas chromatography-mass spectrometry method for determination of metoprolol in the patients with hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19782235/),[ng] / [ml],15,270297,DB00264,Metoprolol
,23097090,AUC,"The clinical study showed that the metoprolol pharmakokinetics is enantioselective, with the observation of higher area under the curve (AUC)(0-∞) values for S-(-)-metoprolol (AUC(S-(-)) /AUC(R-(+)) = 1.81) and the favoring of the formation of the new chiral center 1'R of α-hydroxymetoprolol (AUC(0-∞) (1'R/1'S) = 2.78).",Stereoselective determination of metoprolol and its metabolite α-hydroxymetoprolol in plasma by LC-MS/MS: application to pharmacokinetics during pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097090/),,1.81,271747,DB00264,Metoprolol
,23097090,AUC(0-∞),"The clinical study showed that the metoprolol pharmakokinetics is enantioselective, with the observation of higher area under the curve (AUC)(0-∞) values for S-(-)-metoprolol (AUC(S-(-)) /AUC(R-(+)) = 1.81) and the favoring of the formation of the new chiral center 1'R of α-hydroxymetoprolol (AUC(0-∞) (1'R/1'S) = 2.78).",Stereoselective determination of metoprolol and its metabolite α-hydroxymetoprolol in plasma by LC-MS/MS: application to pharmacokinetics during pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097090/),,2.,271748,DB00264,Metoprolol
<,21128757,F,"At doses where metoprolol exhibited dose-independent pharmacokinetics (1 and 2 mg/kg), complete absorption (>99.2%) and low F (<0.245) after oral administration were observed.",Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21128757/),,0.245,273791,DB00264,Metoprolol
,21128757,first-pass extraction ratio (E(G),"The intestinal and hepatic first-pass extraction ratio (E(G) and E(H), respectively) of metoprolol were approximately 0.45 and 0.60, respectively (equivalent to approximately 45% and 30% of orally administered dose, respectively), suggesting considerable contribution of intestinal first-pass extraction to the low F of metoprolol in rats.",Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21128757/),,0.45,273792,DB00264,Metoprolol
,21128757,first-pass extraction ratio (E(G),"The intestinal and hepatic first-pass extraction ratio (E(G) and E(H), respectively) of metoprolol were approximately 0.45 and 0.60, respectively (equivalent to approximately 45% and 30% of orally administered dose, respectively), suggesting considerable contribution of intestinal first-pass extraction to the low F of metoprolol in rats.",Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21128757/),,0.60,273793,DB00264,Metoprolol
,21128757,first-pass extraction ratio (E(G),"The intestinal and hepatic first-pass extraction ratio (E(G) and E(H), respectively) of metoprolol were approximately 0.45 and 0.60, respectively (equivalent to approximately 45% and 30% of orally administered dose, respectively), suggesting considerable contribution of intestinal first-pass extraction to the low F of metoprolol in rats.",Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21128757/),%,45,273794,DB00264,Metoprolol
,21128757,E(H),"The intestinal and hepatic first-pass extraction ratio (E(G) and E(H), respectively) of metoprolol were approximately 0.45 and 0.60, respectively (equivalent to approximately 45% and 30% of orally administered dose, respectively), suggesting considerable contribution of intestinal first-pass extraction to the low F of metoprolol in rats.",Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21128757/),,0.45,273795,DB00264,Metoprolol
,21128757,E(H),"The intestinal and hepatic first-pass extraction ratio (E(G) and E(H), respectively) of metoprolol were approximately 0.45 and 0.60, respectively (equivalent to approximately 45% and 30% of orally administered dose, respectively), suggesting considerable contribution of intestinal first-pass extraction to the low F of metoprolol in rats.",Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21128757/),,0.60,273796,DB00264,Metoprolol
,21128757,E(H),"The intestinal and hepatic first-pass extraction ratio (E(G) and E(H), respectively) of metoprolol were approximately 0.45 and 0.60, respectively (equivalent to approximately 45% and 30% of orally administered dose, respectively), suggesting considerable contribution of intestinal first-pass extraction to the low F of metoprolol in rats.",Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21128757/),%,45,273797,DB00264,Metoprolol
,21128757,E(H),"The intestinal and hepatic first-pass extraction ratio (E(G) and E(H), respectively) of metoprolol were approximately 0.45 and 0.60, respectively (equivalent to approximately 45% and 30% of orally administered dose, respectively), suggesting considerable contribution of intestinal first-pass extraction to the low F of metoprolol in rats.",Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21128757/),%,30,273798,DB00264,Metoprolol
,21128757,E(G),"The predicted E(G) values were in good agreement with the observed in vivo E(G) (0.492-0.443), suggesting the utility of the prediction of in vivo intestinal first-pass extraction from the in vitro clearance using intestinal microsomes.",Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21128757/),,0.492-0.443,273799,DB00264,Metoprolol
